{"gene":"MSTN","run_date":"2026-04-28T18:30:28","timeline":{"discoveries":[{"year":1997,"finding":"GDF-8 (myostatin) is expressed specifically in developing and adult skeletal muscle; targeted disruption in mice causes a large and widespread increase in skeletal muscle mass (2–3× per muscle), resulting from both muscle cell hyperplasia and hypertrophy, establishing myostatin as a negative regulator of skeletal muscle growth.","method":"Gene targeting / knockout mouse, muscle weight measurements, histology","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — original knockout study, widely replicated across species","pmids":["9139826"],"is_preprint":false},{"year":1997,"finding":"Loss-of-function mutations in the myostatin coding sequence (11-bp deletion causing frameshift in Belgian Blue; C→Y missense in conserved cysteine in Piedmontese) underlie the double-muscled phenotype in cattle, confirming myostatin as a negative regulator of muscle mass in cattle.","method":"cDNA cloning, sequence analysis of normal and double-muscled cattle, expression profiling","journal":"Genome research / PNAS","confidence":"High","confidence_rationale":"Tier 1 — direct mutation identification confirmed by two independent groups in two breeds","pmids":["9314496","9356471","9288100"],"is_preprint":false},{"year":2001,"finding":"Mature myostatin protein consists of a noncovalently held complex of the N-terminal propeptide and a disulfide-linked C-terminal dimer; the C-terminal dimer binds the activin type II receptors ActRIIB (high affinity) and ActRIIA (lower affinity). Transgenic overexpression of the propeptide, follistatin, or a dominant-negative ActRIIB in skeletal muscle each produce dramatic muscle mass increases comparable to myostatin knockouts, establishing these as functional inhibitors of the pathway in vivo.","method":"Protein purification from mammalian cells, receptor binding assays, transgenic mouse overexpression with muscle mass phenotyping","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1 — biochemical characterization plus in vivo genetic epistasis, foundational study","pmids":["11459935"],"is_preprint":false},{"year":2001,"finding":"The GDF-8 propeptide forms a noncovalent complex with mature GDF-8 (shown by size exclusion chromatography and chemical crosslinking), inhibits GDF-8 biological activity in a reporter-gene assay, and blocks specific GDF-8 binding to L6 myoblast cells, identifying the propeptide as a direct inhibitor that acts by preventing receptor binding.","method":"Size exclusion chromatography, chemical crosslinking, cell-based reporter assay, radioligand receptor-binding competition","journal":"Growth factors","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal in vitro methods in single study","pmids":["11519824"],"is_preprint":false},{"year":2002,"finding":"Circulating myostatin in normal mouse and human serum is bound in latent complexes with at least two major inhibitory proteins: the myostatin propeptide (accounting for >70% of serum myostatin) and the follistatin-related gene product FLRG. FLRG was confirmed to bind mature myostatin directly and inhibit its activity in a reporter assay.","method":"Affinity purification with anti-myostatin monoclonal antibody, mass spectrometry, Western blot, recombinant protein binding, luciferase reporter assay","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — immunoprecipitation/MS identification plus functional validation, in vivo relevance confirmed","pmids":["12194980"],"is_preprint":false},{"year":2003,"finding":"Myostatin signals via ActRIIB as the primary type II receptor, then partners with ALK4 (ActRIB) or ALK5 (TβRI) as type I receptors to phosphorylate Smad2/Smad3, activating a TGF-β-like pathway. Myostatin inhibits BMP7- but not BMP2-mediated adipogenic differentiation by competing for ActRIIB, thereby blocking adipogenesis.","method":"Receptor binding assays, reporter gene assays, co-immunoprecipitation, siRNA knockdown, BMP competition binding","journal":"Molecular and Cellular Biology","confidence":"High","confidence_rationale":"Tier 1–2 — receptor characterization with multiple orthogonal methods plus functional pathway dissection","pmids":["14517293"],"is_preprint":false},{"year":2003,"finding":"GASP-1 (growth and differentiation factor-associated serum protein-1), containing whey acidic protein, Kazal, two Kunitz, netrin, and follistatin-like domains, is identified as an endogenous serum-binding protein of myostatin. GASP-1 binds both mature myostatin and the myostatin propeptide directly and inhibits mature myostatin biological activity but not activin activity.","method":"Affinity purification from serum, mass spectrometry, recombinant protein binding, luciferase reporter assay","journal":"Molecular Endocrinology","confidence":"High","confidence_rationale":"Tier 1–2 — endogenous complex identified by MS, binding and function confirmed with recombinant proteins","pmids":["12595574"],"is_preprint":false},{"year":2003,"finding":"GDF-8 treatment of porcine embryonic myogenic cells suppresses proliferation and increases IGFBP-3 protein and mRNA production; a neutralizing anti-IGFBP-3 antibody partially rescues GDF-8-induced proliferation suppression, indicating IGFBP-3 mediates part of GDF-8's anti-proliferative effect in myogenic cells.","method":"Cell proliferation assay, ELISA/immunoblot for IGFBP-3, antibody neutralization","journal":"Journal of Cellular Physiology","confidence":"Medium","confidence_rationale":"Tier 2–3 — functional antibody rescue confirms mechanistic role, single lab","pmids":["14502562"],"is_preprint":false},{"year":2004,"finding":"A child with exceptional muscle hypertrophy was found to carry a mutation in the human MSTN gene, demonstrating that myostatin regulates muscle mass in humans.","method":"Clinical genetics, sequencing of human MSTN gene in patient","journal":"New England Journal of Medicine","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function human mutation with defined phenotypic readout; landmark human validation","pmids":["15215484"],"is_preprint":false},{"year":2009,"finding":"Myostatin inhibits activation of the Akt/mTOR/p70S6K protein synthesis pathway in myoblasts and myotubes, requiring Smad2 and Smad3 downstream of ActRII/ALK receptors. Blockade of RAPTOR (TORC1 component) amplifies myostatin-induced Smad2 phosphorylation, establishing a cross-talk whereby Akt suppression by myostatin feeds back to enhance Smad signaling. Myostatin decreases myotube diameter without upregulating atrophy E3 ligases MuRF1/MAFbx, instead suppressing differentiation-associated genes.","method":"siRNA knockdown of RAPTOR/RICTOR, phospho-protein immunoblot, myotube diameter measurement, gene expression","journal":"American Journal of Physiology – Cell Physiology","confidence":"High","confidence_rationale":"Tier 1–2 — mechanistic dissection with siRNA epistasis and multiple pathway readouts, widely cited","pmids":["19357233"],"is_preprint":false},{"year":1998,"finding":"The human myostatin gene comprises three exons and two introns, maps to chromosomal region 2q33.2, is transcribed as a 3.1-kb mRNA encoding a 375-aa precursor protein, and is expressed in skeletal muscle as a secreted 26-kDa mature glycoprotein detectable in plasma. Serum and intramuscular myostatin concentrations are elevated in HIV-infected men with weight loss and correlate inversely with fat-free mass, implicating myostatin in human muscle wasting.","method":"Molecular cloning, RT-PCR, Western blot, immunohistochemistry, ELISA","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 — gene structure characterized, protein detected in plasma with functional context","pmids":["9843994"],"is_preprint":false},{"year":1999,"finding":"Myostatin mRNA and protein are expressed not only in skeletal muscle but also in fetal and adult heart tissue, with protein localized to Purkinje fibers and cardiomyocytes; myostatin expression is upregulated in cardiomyocytes surrounding the infarct zone after myocardial infarction, suggesting a role in cardiac physiology.","method":"RT-PCR, Western blot, immunohistochemistry on heart sections, myocardial infarction model","journal":"Journal of Cellular Physiology","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization and regulated expression in cardiac tissue with disease model","pmids":["10362012"],"is_preprint":false},{"year":2013,"finding":"Hyperammonemia (as occurs in liver cirrhosis) induces myostatin expression in skeletal muscle via an NF-κB-dependent mechanism: ammonia activates IκB kinase, triggers NF-κB nuclear translocation, and the NF-κB p65 subunit binds specific sites in the myostatin promoter to drive transcription. Pharmacologic inhibition or gene silencing of NF-κB abolishes this upregulation.","method":"C2C12 myotube ammonium acetate treatment, NF-κB ChIP, siRNA knockdown, IKK inhibitor, primary muscle cell cultures, in vivo mouse hyperammonemia model","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 1–2 — ChIP identifies direct promoter binding, confirmed by siRNA and pharmacological inhibition in vitro and in vivo","pmids":["24145431"],"is_preprint":false},{"year":2017,"finding":"Despite 90% amino acid sequence identity, GDF11 is a more potent activator of SMAD2/3 and signals more effectively through ALK4/5/7 than GDF8. Crystal structures of the GDF11:FS288 complex, apo-GDF8, and apo-GDF11 reveal unique structural features in the type I receptor binding site of each ligand; substitution of GDF11 residues into GDF8 confers enhanced SMAD2/3 signaling activity to GDF8.","method":"Crystal structure determination, SMAD2/3 phosphorylation assays, chimeric protein mutagenesis, receptor signaling assays","journal":"BMC Biology","confidence":"High","confidence_rationale":"Tier 1 — crystal structures plus mutagenesis and functional validation in single study","pmids":["28257634"],"is_preprint":false},{"year":2019,"finding":"The WFIKKN2 follistatin domain (FSD) directly binds GDF8 and GDF11 and blocks their interaction with the type II receptor ActRIIB (shown by native gel shift and surface plasmon resonance). Crystal structure of the WFIKKN2 FSD at 1.39 Å identified surface-exposed residues that, when mutated to alanine, reduce GDF8 antagonism in full-length WFIKKN2. The WFIKKN2 FSD inhibits GDF8 via different binding contacts than follistatin or FSTL3.","method":"Protein crystallography (1.39 Å), surface plasmon resonance, native gel shift, alanine-scanning mutagenesis, functional antagonism assay","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mutagenesis and SPR binding validation","pmids":["30814254"],"is_preprint":false},{"year":2021,"finding":"Tolloid-family metalloproteases activate latent GDF8 by cleaving the prodomain at residue D99. Sequential alanine mutagenesis identified Y94 and D92 as critical residues adjacent to the scissile bond for tolloid recognition; D92A and Y94A mutations impede tolloid-mediated cleavage but allow full activation under acidic conditions. Co-expression of tolloid-resistant prodomain mutants with wild-type GDF8 suppresses GDF8 activity in a dominant-negative manner.","method":"Alanine-scanning mutagenesis of GDF8 prodomain, in vitro protease cleavage assays using astacin domain of Tll1, latent complex purification, reporter assay","journal":"Biochemical Journal","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro cleavage assay with mutagenesis identifies specific recognition residues","pmids":["33876824"],"is_preprint":false},{"year":2014,"finding":"The small molecules dorsomorphin and LDN-193189 inhibit GDF8/myostatin signaling by binding the type II receptor ActRIIA (crystal structure of ActRIIA:dorsomorphin solved), blocking GDF8-induced Smad2/3 phosphorylation and repression of myogenic transcription factors, thereby rescuing myoblast differentiation and promoting contractile myotubular network activity.","method":"Crystal structure determination of ActRIIA:dorsomorphin, Smad2/3 phosphorylation assays, myoblast differentiation assays, quantitative live-cell microscopy","journal":"Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure plus functional assays with mechanistic pathway readout","pmids":["25368322"],"is_preprint":false},{"year":2020,"finding":"In MSTN mutant (MSTN-/+) satellite cells, SMAD2/SMAD3 complex binding to the TET1 promoter normally represses TET1 transcription. Loss of MSTN signaling reduces SMAD2/SMAD3 occupancy at the TET1 promoter (shown by ChIP-qPCR), increasing TET1 demethylase expression and reducing DNA methylation of PAX3, PAX7, MyoD, and MyoG promoters/gene bodies, thereby promoting myogenic differentiation.","method":"ChIP-qPCR, bisulfite sequencing (methylation analysis), TET1 overexpression and knockdown, myotube fusion index","journal":"International Journal of Biological Sciences","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP-qPCR directly demonstrates SMAD2/3 binding to TET1 promoter; single lab","pmids":["32210722"],"is_preprint":false},{"year":2020,"finding":"GDF8 upregulates SERPINE1 (PAI-1) expression in human granulosa-lutein cells via the ALK5-mediated SMAD2/3-SMAD4 signaling pathway (not via ERK1/2, which is also activated but is not required for SERPINE1 induction), and requires TP53; this SERPINE1 upregulation mediates GDF8-induced glucose metabolism defects.","method":"siRNA knockdown of ALK5, SMAD2, SMAD3, ERK1/2, TP53; pharmacological inhibitor SB-431542; transcriptome sequencing; DHEA-induced PCOS mouse model","journal":"Molecular Therapy – Nucleic Acids","confidence":"Medium","confidence_rationale":"Tier 2 — multiple siRNA and pharmacological approaches dissect the pathway; single lab","pmids":["33425488"],"is_preprint":false},{"year":2020,"finding":"GDF8 upregulates FSTL3 expression in human extravillous cytotrophoblast cells via the ALK5-SMAD2/3 signaling pathway, and this FSTL3 induction promotes trophoblast cell invasiveness; siRNA knockdown of ALK5 or SMAD2/3 abolishes the effect.","method":"siRNA knockdown, immunoblot, invasion assay (Matrigel), pharmacological inhibitor","journal":"Frontiers in Cell and Developmental Biology","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA epistasis identifies the ALK5-SMAD2/3 pathway; single lab","pmids":["33195207"],"is_preprint":false},{"year":2021,"finding":"GDF-8 upregulates MMP2 (but not MMP9) expression in human extravillous cytotrophoblast (HTR-8/SVneo) cells via the ALK5-SMAD2/3 signaling pathway; knockdown of MMP2 attenuates GDF-8-induced cell invasiveness, linking the ALK5-SMAD2/3-MMP2 axis to trophoblast invasion.","method":"siRNA knockdown of ALK5, SMAD2/3, MMP2; immunoblot; invasion assay","journal":"Reproduction","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA epistasis with functional invasiveness readout; single lab","pmids":["34432647"],"is_preprint":false},{"year":2021,"finding":"GDF-8 stimulates aromatase (CYP19A1) expression and estradiol production in human granulosa-lutein cells via ALK5-mediated SMAD2/3 signaling; pharmacological blockade of ALK5 with SB431542 alleviates ovarian hyperstimulation syndrome symptoms and aromatase upregulation in a rat OHSS model.","method":"In vitro granulosa cell treatment, siRNA knockdown of ALK5/SMAD2/3, rat OHSS model, SB431542 pharmacological inhibition, ELISA","journal":"International Journal of Biological Sciences","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro mechanism confirmed in vivo with pharmacological inhibition; single lab","pmids":["34239360"],"is_preprint":false},{"year":2019,"finding":"GDF8 activates p38 MAPK signaling in cumulus cells and oocytes during in vitro maturation of porcine oocytes, acting through ActRIIb and Alk4/5 receptors; p38 MAPK phosphorylation alters downstream gene expression (Nrf2, Bcl-2, Has2, Ptx3, TNFAIP6) and reduces intracellular ROS, improving oocyte quality and embryo developmental competence.","method":"Receptor gene transcription assay, phospho-p38 immunoblot, gene expression analysis, ROS measurement, IVF/PA developmental assay","journal":"Theriogenology","confidence":"Medium","confidence_rationale":"Tier 2 — receptor induction and p38 phosphorylation linked to functional outcome; single lab","pmids":["28708509"],"is_preprint":false},{"year":2019,"finding":"MSTN attenuates pathological cardiac hypertrophy and excessive autophagy by directly inactivating AMPK/mTOR signaling and activating PPARγ/NF-κB signaling; additionally, MSTN downregulates miR-128 expression (induced by pressure overload/Ang II), preventing miR-128-mediated suppression of its target PPARγ, thereby maintaining the PPARγ/NF-κB axis.","method":"Myostatin knockout (MSTN-/-) mice, abdominal aorta coarctation model, Ang II treatment in vitro and in vivo, AMPK/mTOR/PPARγ/NF-κB pathway immunoblots, miR-128 overexpression/inhibition","journal":"Molecular Therapy – Nucleic Acids","confidence":"Medium","confidence_rationale":"Tier 2 — knockout + pathway immunoblots + miRNA manipulation in vitro and in vivo; single lab","pmids":["31923740"],"is_preprint":false},{"year":2014,"finding":"Suppression of myostatin by an anti-MSTN polyclonal antibody in diet-induced obese rats reverses insulin resistance by enhancing PI3K activity, Akt phosphorylation, GLUT4 expression, and mTOR phosphorylation, while inhibiting FoxO1 phosphorylation, without affecting GSK-3β phosphorylation, defining MSTN/PI3K/Akt/mTOR and MSTN/PI3K/Akt/FoxO1 as relevant signaling axes.","method":"Anti-MSTN antibody treatment in obese rats, PI3K activity assay, phospho-protein immunoblots, GLUT4 protein expression","journal":"Biotechnology Letters","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological inhibition in vivo with multiple pathway readouts; single lab","pmids":["25048241"],"is_preprint":false},{"year":2025,"finding":"Dual blockade of GDF8 and activin A (the two major ActRIIA/B ligands mediating muscle minimization) prevents GLP-1 receptor agonist-induced muscle loss and increases muscle mass in obese mice and non-human primates; this muscle preservation additionally enhances fat loss, demonstrating that GDF8 and activin A together are the principal ligands through which the ActRII receptor pathway reduces muscle mass.","method":"Dual antibody blockade in obese mouse and NHP models, body composition analysis (muscle/fat mass), GLP-1 agonist co-treatment","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 — dual blockade in two independent animal models identifies GDF8+activin A as non-redundant ActRII ligands for muscle mass regulation","pmids":["40360507"],"is_preprint":false},{"year":2008,"finding":"Myostatin deficiency leads to increased osteogenic differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) in vitro; BMSCs express the myostatin receptor AcvrIIB, and recombinant myostatin decreases expression of osteogenic factors BMP-2 and IGF-1 in mechanically loaded BMSCs. This osteogenic advantage is abolished by unloading, indicating myostatin suppresses mechanosensitivity-dependent osteogenic factor expression.","method":"BMSC isolation from myostatin-null mice, osteogenic differentiation assays, immunofluorescence for AcvrIIB, recombinant myostatin treatment, hindlimb unloading model","journal":"Bone","confidence":"Medium","confidence_rationale":"Tier 2 — receptor expression confirmed in target cells, gain/loss of function in vitro and in vivo; single lab","pmids":["17383950"],"is_preprint":false},{"year":2011,"finding":"Myostatin treatment of bone marrow stromal cells (BMSCs) and epiphyseal growth plate chondrocytes inhibits their proliferation; myostatin suppresses chondrogenic differentiation of BMSCs by reducing collagen type II synthesis and significantly downregulating Sox9 mRNA expression, establishing a direct inhibitory role for myostatin in chondrogenesis.","method":"Proliferation assays on myostatin-deficient mouse BMSCs and chondrocytes, recombinant myostatin treatment, collagen type II ELISA, real-time PCR for Sox9","journal":"Growth Factors","confidence":"Medium","confidence_rationale":"Tier 2 — direct recombinant protein treatment with defined molecular readout; single lab","pmids":["21756198"],"is_preprint":false},{"year":2020,"finding":"A single amino acid deletion in the MSTN propeptide region (deletion of cysteine 42, caused by a 3-bp deletion in exon 1) is sufficient to produce muscle hyperplasia (increased fiber number) without hypertrophy, and reduces fat pad weight in homozygous quail, demonstrating that cysteine 42 in the propeptide is functionally important for MSTN activity in avian species.","method":"CRISPR/Cas9 adenoviral gene editing in quail, genotyping, histology, body composition analysis","journal":"International Journal of Molecular Sciences","confidence":"Medium","confidence_rationale":"Tier 2 — defined single-residue deletion with characterized phenotypic readout in vivo","pmids":["32098368"],"is_preprint":false}],"current_model":"Myostatin (MSTN/GDF8) is synthesized as a precursor that is proteolytically processed into a propeptide–C-terminal dimer latent complex; tolloid metalloproteases cleave the prodomain at D99 (requiring Y94 and D92 for recognition) to activate the latent complex, and the active C-terminal dimer signals by binding ActRIIB (primarily) or ActRIIA, which recruits ALK4 or ALK5 as a type I receptor to phosphorylate Smad2/Smad3 and simultaneously suppresses Akt/mTOR/p70S6K, thereby inhibiting myoblast differentiation, reducing myotube size, blocking adipogenesis (via BMP7/ActRIIB competition), and suppressing osteogenic and chondrogenic differentiation; endogenous inhibition is achieved by noncovalent binding of the propeptide, FLRG, and GASP-1 in serum, and by follistatin/WFIKKN2 (which block type II receptor access), while NF-κB directly drives myostatin transcription under hyperammonemic conditions and SMAD2/3 represses the TET1 demethylase promoter to maintain hypermethylation of myogenic genes."},"narrative":{"teleology":[{"year":1997,"claim":"Establishing myostatin as a negative regulator of muscle growth: targeted disruption in mice and natural loss-of-function mutations in cattle independently demonstrated that MSTN loss causes 2–3× increases in skeletal muscle mass through both hyperplasia and hypertrophy, defining the gene's core biological function.","evidence":"Knockout mouse phenotyping (Nature) and cattle breed mutation identification (Genome Research, PNAS)","pmids":["9139826","9314496","9356471","9288100"],"confidence":"High","gaps":["Mechanism of action and receptor identity unknown","Relative contribution of hyperplasia vs. hypertrophy unresolved","No human validation yet"]},{"year":2001,"claim":"Defining the latent complex and receptor system: biochemical studies showed that mature myostatin is a disulfide-linked C-terminal dimer held in an inactive complex by its propeptide, which directly blocks receptor binding; the dimer binds ActRIIB with high affinity and ActRIIA with lower affinity, and transgenic overexpression of the propeptide, follistatin, or dominant-negative ActRIIB phenocopied myostatin knockouts.","evidence":"Protein purification, receptor binding assays, size exclusion chromatography, chemical crosslinking, and transgenic mouse muscle phenotyping","pmids":["11459935","11519824"],"confidence":"High","gaps":["Type I receptor partners not yet identified","Mechanism of latent complex activation unknown","Intracellular signaling cascade uncharacterized"]},{"year":2003,"claim":"Mapping the intracellular signaling pathway and identifying endogenous serum inhibitors: myostatin was shown to signal through ALK4/ALK5 to phosphorylate Smad2/3, and two additional endogenous inhibitory proteins—FLRG and GASP-1—were identified in serum complexes with myostatin alongside the propeptide, establishing a multi-layered extracellular regulation system.","evidence":"Receptor co-IP, siRNA knockdown, reporter assays, affinity purification/MS from serum, recombinant protein binding","pmids":["14517293","12194980","12595574"],"confidence":"High","gaps":["Relative stoichiometric contributions of propeptide, FLRG, GASP-1, and follistatin in vivo unclear","Cross-talk with non-Smad pathways not defined","Mechanism of latent complex activation still unknown"]},{"year":2004,"claim":"Human genetic validation: identification of a loss-of-function MSTN mutation in a child with exceptional muscle hypertrophy confirmed that myostatin's role as a muscle growth inhibitor is conserved in humans.","evidence":"Clinical genetics and MSTN gene sequencing in a hyper-muscular child","pmids":["15215484"],"confidence":"High","gaps":["Only a single human case reported","Dose-response and heterozygous phenotype in humans poorly defined"]},{"year":2009,"claim":"Dissecting Akt/mTOR suppression as a parallel mechanism: myostatin was shown to inhibit the Akt/mTOR/p70S6K protein synthesis pathway in a Smad2/3-dependent manner, with reciprocal cross-talk whereby TORC1 blockade amplifies Smad2 phosphorylation, explaining myostatin's ability to reduce myotube size independently of atrophy E3 ligases.","evidence":"siRNA knockdown of RAPTOR/RICTOR, phospho-protein immunoblots, myotube diameter measurements","pmids":["19357233"],"confidence":"High","gaps":["Mechanism linking Smad2/3 to Akt suppression not fully resolved","In vivo validation of cross-talk incomplete","Atrophy-independent fiber size reduction mechanism unclear"]},{"year":2013,"claim":"Identifying transcriptional regulation of MSTN itself: NF-κB p65 was shown to bind directly to the myostatin promoter under hyperammonemic conditions, driving transcriptional upregulation—a mechanism linking liver disease–associated sarcopenia to myostatin.","evidence":"ChIP on myostatin promoter, NF-κB siRNA and IKK inhibitor in C2C12 myotubes and mouse hyperammonemia model","pmids":["24145431"],"confidence":"High","gaps":["Other transcriptional regulators of MSTN promoter not systematically identified","Whether NF-κB drives MSTN in non-hepatic wasting conditions unknown"]},{"year":2017,"claim":"Structural basis for signaling specificity: crystal structures of apo-GDF8 and apo-GDF11 revealed that despite 90% sequence identity, unique features in the type I receptor binding site explain GDF11's higher SMAD2/3 signaling potency, and chimeric mutagenesis confirmed these residues as determinants of signaling output.","evidence":"X-ray crystallography, chimeric mutagenesis, SMAD2/3 phosphorylation assays","pmids":["28257634"],"confidence":"High","gaps":["Full ternary complex structure (ligand–type I–type II) not solved","Structural basis for differential receptor recruitment in cells unknown"]},{"year":2019,"claim":"Structural mechanism of WFIKKN2 inhibition: crystallography and mutagenesis demonstrated that the WFIKKN2 follistatin domain blocks GDF8 access to ActRIIB through binding contacts distinct from those used by follistatin or FSTL3, revealing non-redundant modes of extracellular antagonism.","evidence":"1.39 Å crystal structure of WFIKKN2 FSD, SPR, native gel shift, alanine-scanning mutagenesis","pmids":["30814254"],"confidence":"High","gaps":["Full WFIKKN2–GDF8 co-crystal structure not available","In vivo contribution of WFIKKN2 vs. other antagonists not quantified"]},{"year":2020,"claim":"Epigenetic mechanism downstream of Smad signaling: SMAD2/3 occupancy at the TET1 promoter was shown to repress TET1 demethylase transcription, maintaining DNA methylation at myogenic gene promoters (PAX3, PAX7, MyoD, MyoG); MSTN loss derepresses TET1, reducing methylation and promoting differentiation.","evidence":"ChIP-qPCR for SMAD2/3 at TET1 promoter, bisulfite sequencing, TET1 knockdown/overexpression in MSTN+/- satellite cells","pmids":["32210722"],"confidence":"Medium","gaps":["Single-lab finding awaiting independent replication","Whether TET1 regulation is muscle-specific or systemic unknown","Contribution relative to direct transcriptional Smad targets not quantified"]},{"year":2021,"claim":"Defining prodomain activation mechanism: tolloid metalloproteases were shown to cleave the GDF8 prodomain at D99, with Y94 and D92 identified as critical recognition residues; tolloid-resistant prodomain mutants act as dominant-negative inhibitors.","evidence":"In vitro cleavage assay with Tll1 astacin domain, alanine-scanning mutagenesis, reporter assays","pmids":["33876824"],"confidence":"High","gaps":["In vivo validation of tolloid-dependent activation kinetics missing","Structural basis of tolloid–prodomain recognition not solved","Alternative activation pathways (e.g., acid pH) not fully characterized"]},{"year":2025,"claim":"Demonstrating non-redundancy of GDF8 and activin A: dual antibody blockade of both ligands—but not either alone—fully prevented GLP-1 agonist–induced muscle loss and enhanced fat loss in obese mice and NHPs, establishing GDF8 and activin A as the two principal ActRII ligands limiting muscle mass.","evidence":"Dual antibody blockade in obese mouse and non-human primate models with body composition analysis","pmids":["40360507"],"confidence":"High","gaps":["Relative contribution of each ligand to muscle vs. fat regulation not individually quantified","Long-term safety of dual blockade unknown","Whether other ActRII ligands contribute in specific disease contexts untested"]},{"year":null,"claim":"Key unresolved questions include the full ternary structure of the GDF8–type I–type II receptor signaling complex, the quantitative in vivo contributions of each extracellular antagonist (propeptide, FLRG, GASP-1, follistatin, WFIKKN2), the complete set of transcriptional regulators of the MSTN promoter beyond NF-κB, and the mechanistic basis for myostatin's non-muscle roles in cardiac, bone, and reproductive tissues.","evidence":"","pmids":[],"confidence":"High","gaps":["Ternary receptor complex structure unsolved","Systematic in vivo dissection of antagonist hierarchy lacking","Non-muscle signaling mechanisms poorly defined at molecular level"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,2,8,25]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[5,9,23]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[2,3,4,6,10]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5,9,17]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[0,1,8,26,27]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[24]},{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[2,3,15]}],"complexes":["Latent myostatin complex (propeptide–mature GDF8 dimer)"],"partners":["ACVR2B","ACVR2A","ACVR1B","TGFBR1","FSTL3","WFIKKN2","FLRG","FSTL1"],"other_free_text":[]},"mechanistic_narrative":"Myostatin (MSTN/GDF8) is a secreted TGF-β superfamily member that functions as a master negative regulator of skeletal muscle mass and additionally suppresses osteogenic, chondrogenic, and adipogenic differentiation. It is synthesized as a precursor that is proteolytically processed into a latent complex of a disulfide-linked C-terminal dimer held noncovalently by the propeptide; activation requires tolloid metalloprotease cleavage of the prodomain at D99, with recognition dependent on Y94 and D92 [PMID:33876824]. The active dimer signals primarily through ActRIIB (and ActRIIA), recruiting ALK4 or ALK5 as type I receptors to phosphorylate Smad2/Smad3, which inhibits myoblast differentiation, suppresses the Akt/mTOR/p70S6K protein synthesis axis, and epigenetically maintains hypermethylation of myogenic gene promoters by repressing TET1 transcription [PMID:19357233, PMID:32210722, PMID:14517293]. Loss-of-function mutations in MSTN cause dramatic skeletal muscle hypertrophy and hyperplasia in mice, cattle, and humans [PMID:9139826, PMID:9314496, PMID:15215484]."},"prefetch_data":{"uniprot":{"accession":"O14793","full_name":"Growth/differentiation factor 8","aliases":["Myostatin"],"length_aa":375,"mass_kda":42.8,"function":"Acts specifically as a negative regulator of skeletal muscle growth","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O14793/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MSTN","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MSTN","total_profiled":1310},"omim":[{"mim_id":"614160","title":"MUSCLE HYPERTROPHY; MSLHP","url":"https://www.omim.org/entry/614160"},{"mim_id":"609101","title":"F-BOX ONLY PROTEIN 30; FBXO30","url":"https://www.omim.org/entry/609101"},{"mim_id":"605343","title":"FOLLISTATIN-LIKE 3; FSTL3","url":"https://www.omim.org/entry/605343"},{"mim_id":"604488","title":"TITIN-CAP; TCAP","url":"https://www.omim.org/entry/604488"},{"mim_id":"603936","title":"GROWTH/DIFFERENTIATION FACTOR 11; GDF11","url":"https://www.omim.org/entry/603936"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"skeletal muscle","ntpm":9.4},{"tissue":"tongue","ntpm":14.3}],"url":"https://www.proteinatlas.org/search/MSTN"},"hgnc":{"alias_symbol":[],"prev_symbol":["GDF8"]},"alphafold":{"accession":"O14793","domains":[{"cath_id":"2.10.90.10","chopping":"41-97_270-375","consensus_level":"high","plddt":83.551,"start":41,"end":375},{"cath_id":"2.60.40","chopping":"123-250","consensus_level":"high","plddt":85.133,"start":123,"end":250}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O14793","model_url":"https://alphafold.ebi.ac.uk/files/AF-O14793-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O14793-F1-predicted_aligned_error_v6.png","plddt_mean":78.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MSTN","jax_strain_url":"https://www.jax.org/strain/search?query=MSTN"},"sequence":{"accession":"O14793","fasta_url":"https://rest.uniprot.org/uniprotkb/O14793.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O14793/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O14793"}},"corpus_meta":[{"pmid":"9314496","id":"PMC_9314496","title":"Mutations in myostatin (GDF8) in double-muscled Belgian Blue and Piedmontese cattle.","date":"1997","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/9314496","citation_count":844,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11519824","id":"PMC_11519824","title":"GDF-8 propeptide binds to GDF-8 and antagonizes biological activity by inhibiting GDF-8 receptor binding.","date":"2001","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/11519824","citation_count":206,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20190380","id":"PMC_20190380","title":"Myostatin (GDF-8) as a key factor linking muscle mass and bone structure.","date":"2010","source":"Journal of musculoskeletal & neuronal interactions","url":"https://pubmed.ncbi.nlm.nih.gov/20190380","citation_count":166,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17383950","id":"PMC_17383950","title":"Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading.","date":"2007","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/17383950","citation_count":144,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20098749","id":"PMC_20098749","title":"A sequence polymorphism in MSTN predicts sprinting ability and racing stamina in thoroughbred horses.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20098749","citation_count":144,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26354037","id":"PMC_26354037","title":"Generation of gene-modified goats targeting MSTN and FGF5 via zygote injection of CRISPR/Cas9 system.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26354037","citation_count":133,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16849634","id":"PMC_16849634","title":"GRB14, GPD1, and GDF8 as potential network collaborators in weight loss-induced improvements in insulin action in human skeletal muscle.","date":"2006","source":"Physiological genomics","url":"https://pubmed.ncbi.nlm.nih.gov/16849634","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20932346","id":"PMC_20932346","title":"A genome-wide SNP-association study confirms a sequence variant (g.66493737C>T) in the equine myostatin (MSTN) gene as the most powerful predictor of optimum racing distance for Thoroughbred racehorses.","date":"2010","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/20932346","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28257634","id":"PMC_28257634","title":"Structural basis for potency differences between GDF8 and GDF11.","date":"2017","source":"BMC biology","url":"https://pubmed.ncbi.nlm.nih.gov/28257634","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10610713","id":"PMC_10610713","title":"Frequent sequence variation in the human myostatin (GDF8) gene as a marker for analysis of muscle-related phenotypes.","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10610713","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11555072","id":"PMC_11555072","title":"Polymorphic variation in the human myostatin (GDF-8) gene and association with strength measures in the Women's Health and Aging Study II cohort.","date":"2001","source":"Journal of the American Geriatrics Society","url":"https://pubmed.ncbi.nlm.nih.gov/11555072","citation_count":76,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18852073","id":"PMC_18852073","title":"Myostatin (GDF-8) deficiency increases fracture callus size, Sox-5 expression, and callus bone volume.","date":"2008","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/18852073","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17996073","id":"PMC_17996073","title":"Evidence for multiple alleles effecting muscling and fatness at the ovine GDF8 locus.","date":"2007","source":"BMC genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17996073","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32071240","id":"PMC_32071240","title":"GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN/GDF11 inhibitor, increases muscle mass but weakens bone.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32071240","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18462481","id":"PMC_18462481","title":"Two single nucleotide polymorphisms in the myostatin (GDF8) gene have significant association with muscle depth of commercial Charollais sheep.","date":"2008","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18462481","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24743319","id":"PMC_24743319","title":"Efficient generation of myostatin (MSTN) biallelic mutations in cattle using zinc finger nucleases.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24743319","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27530319","id":"PMC_27530319","title":"Isozygous and selectable marker-free MSTN knockout cloned pigs generated by the combined use of CRISPR/Cas9 and Cre/LoxP.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27530319","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17890020","id":"PMC_17890020","title":"Myostatin (MSTN) gene duplications in Atlantic salmon (Salmo salar): evidence for different selective pressure on teleost MSTN-1 and -2.","date":"2007","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/17890020","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25368322","id":"PMC_25368322","title":"Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation.","date":"2014","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25368322","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29446146","id":"PMC_29446146","title":"CRISPR/Cas9-mediated MSTN disruption and heritable mutagenesis in goats causes increased body mass.","date":"2018","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/29446146","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32098368","id":"PMC_32098368","title":"Muscle Hyperplasia in Japanese Quail by Single Amino Acid Deletion in MSTN Propeptide.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32098368","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31923740","id":"PMC_31923740","title":"MSTN Attenuates Cardiac Hypertrophy through Inhibition of Excessive Cardiac Autophagy by Blocking AMPK /mTOR and miR-128/PPARγ/NF-κB.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/31923740","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28852138","id":"PMC_28852138","title":"Inhibition of GDF8 (Myostatin) accelerates bone regeneration in diabetes mellitus type 2.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28852138","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20113462","id":"PMC_20113462","title":"Impact of two myostatin (MSTN) mutations on weight gain and lamb carcass classification in Norwegian White Sheep (Ovis aries).","date":"2010","source":"Genetics, selection, evolution : GSE","url":"https://pubmed.ncbi.nlm.nih.gov/20113462","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16003464","id":"PMC_16003464","title":"Effects of the compact mutant myostatin allele Mstn (Cmpt-dl1Abc) introgressed into a high growth mouse line on skeletal muscle cellularity.","date":"2005","source":"Journal of muscle research and cell motility","url":"https://pubmed.ncbi.nlm.nih.gov/16003464","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34247443","id":"PMC_34247443","title":"Production of MSTN-mutated cattle without exogenous gene integration using CRISPR-Cas9.","date":"2021","source":"Biotechnology journal","url":"https://pubmed.ncbi.nlm.nih.gov/34247443","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19251921","id":"PMC_19251921","title":"Investigations into the GDF8 g+6723G-A polymorphism in New Zealand Texel sheep.","date":"2009","source":"Journal of animal science","url":"https://pubmed.ncbi.nlm.nih.gov/19251921","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32210722","id":"PMC_32210722","title":"MSTN Mutant Promotes Myogenic Differentiation by Increasing Demethylase TET1 Expression via the SMAD2/SMAD3 Pathway.","date":"2020","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32210722","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21756198","id":"PMC_21756198","title":"Myostatin (GDF-8) inhibits chondrogenesis and chondrocyte proliferation in vitro by suppressing Sox-9 expression.","date":"2011","source":"Growth factors (Chur, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/21756198","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22205678","id":"PMC_22205678","title":"Immunolocalization of myostatin (GDF-8) following musculoskeletal injury and the effects of exogenous myostatin on muscle and bone healing.","date":"2012","source":"The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society","url":"https://pubmed.ncbi.nlm.nih.gov/22205678","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16100053","id":"PMC_16100053","title":"A directed search in the region of GDF8 for quantitative trait loci affecting carcass traits in Texel sheep.","date":"2005","source":"Journal of animal science","url":"https://pubmed.ncbi.nlm.nih.gov/16100053","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24479661","id":"PMC_24479661","title":"The A55T and K153R polymorphisms of MSTN gene are associated with the strength training-induced muscle hypertrophy among Han Chinese men.","date":"2014","source":"Journal of sports sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24479661","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34109474","id":"PMC_34109474","title":"Long-term, multidomain analyses to identify the breed and allelic effects in MSTN-edited pigs to overcome lameness and sustainably improve nutritional meat production.","date":"2021","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34109474","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21710248","id":"PMC_21710248","title":"Polymorphisms of myostatin gene (MSTN) in four goat breeds and their effects on Boer goat growth performance.","date":"2011","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21710248","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32679613","id":"PMC_32679613","title":"CRISPR/Cas9-mediated MSTN disruption accelerates the growth of Chinese Bama pigs.","date":"2020","source":"Reproduction in domestic animals = Zuchthygiene","url":"https://pubmed.ncbi.nlm.nih.gov/32679613","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20648054","id":"PMC_20648054","title":"Hemizygous deletion of COL3A1, COL5A2, and MSTN causes a complex phenotype with aortic dissection: a lesson for and from true haploinsufficiency.","date":"2010","source":"European journal of human genetics : EJHG","url":"https://pubmed.ncbi.nlm.nih.gov/20648054","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14504233","id":"PMC_14504233","title":"Mapping modifiers affecting muscularity of the myostatin mutant (Mstn(Cmpt-dl1Abc)) compact mouse.","date":"2003","source":"Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14504233","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28074479","id":"PMC_28074479","title":"GDF8 inhibits bone formation and promotes bone resorption in mice.","date":"2017","source":"Clinical and experimental pharmacology & physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28074479","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33425488","id":"PMC_33425488","title":"Aberrant elevation of GDF8 impairs granulosa cell glucose metabolism via upregulating SERPINE1 expression in patients with PCOS.","date":"2020","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/33425488","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30242885","id":"PMC_30242885","title":"CRISPR/Cas9-mediated sheep MSTN gene knockout and promote sSMSCs differentiation.","date":"2018","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30242885","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27289021","id":"PMC_27289021","title":"Establishment and phenotypic analysis of an Mstn knockout rat.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27289021","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30981084","id":"PMC_30981084","title":"Comparison of gene editing efficiencies of CRISPR/Cas9 and TALEN for generation of MSTN knock-out cashmere goats.","date":"2019","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/30981084","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19731204","id":"PMC_19731204","title":"Myostatin (GDF8) single nucleotide polymorphisms in Nellore cattle.","date":"2009","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/19731204","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40360507","id":"PMC_40360507","title":"GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates.","date":"2025","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/40360507","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30922397","id":"PMC_30922397","title":"IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway.","date":"2019","source":"Skeletal muscle","url":"https://pubmed.ncbi.nlm.nih.gov/30922397","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14502562","id":"PMC_14502562","title":"Role of insulin-like growth factor binding protein (IGFBP)-3 in TGF-beta- and GDF-8 (myostatin)-induced suppression of proliferation in porcine embryonic myogenic cell cultures.","date":"2003","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/14502562","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31374285","id":"PMC_31374285","title":"Proteomics insights into the effects of MSTN on muscle glucose and lipid metabolism in genetically edited cattle.","date":"2019","source":"General and comparative endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31374285","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21323579","id":"PMC_21323579","title":"Analysis of the single-nucleotide polymorphism in the 5'UTR and part of intron I of the sheep MSTN gene.","date":"2011","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21323579","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22714921","id":"PMC_22714921","title":"Molecular characterization of myostatin (MSTN) gene and association analysis with growth traits in the bighead carp (Aristichthys nobilis).","date":"2012","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/22714921","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32276422","id":"PMC_32276422","title":"Effective MSTN Gene Knockout by AdV-Delivered CRISPR/Cas9 in Postnatal Chick Leg Muscle.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32276422","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29802684","id":"PMC_29802684","title":"CRISPR/Cas9-mediated specific integration of fat-1 at the goat MSTN locus.","date":"2018","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/29802684","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17551751","id":"PMC_17551751","title":"Characterization of amphioxus GDF8/11 gene, an archetype of vertebrate MSTN and GDF11.","date":"2007","source":"Development genes and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/17551751","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31819500","id":"PMC_31819500","title":"Prevalence of DLL3, CTLA-4 and MSTN Expression in Patients with Small Cell Lung Cancer.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/31819500","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35524183","id":"PMC_35524183","title":"Optimized Cas9:sgRNA delivery efficiently generates biallelic MSTN knockout sheep without affecting meat quality.","date":"2022","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/35524183","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31134482","id":"PMC_31134482","title":"Inefficient ATP synthesis by inhibiting mitochondrial respiration causes lipids to decrease in MSTN-lacking muscles of loach Misgurnus anguillicaudatus.","date":"2019","source":"Functional & integrative genomics","url":"https://pubmed.ncbi.nlm.nih.gov/31134482","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32481564","id":"PMC_32481564","title":"Effect of MSTN Mutation on Growth and Carcass Performance in Duroc x Meishan Hybrid Population.","date":"2020","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/32481564","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31963797","id":"PMC_31963797","title":"Myostatin (MSTN) Gene Indel Variation and Its Associations with Body Traits in Shaanbei White Cashmere Goat.","date":"2020","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/31963797","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19899116","id":"PMC_19899116","title":"Age-related changes in craniofacial morphology in GDF-8 (myostatin)-deficient mice.","date":"2010","source":"Anatomical record (Hoboken, N.J. : 2007)","url":"https://pubmed.ncbi.nlm.nih.gov/19899116","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19505313","id":"PMC_19505313","title":"An insertion in the coding region of the myostatin (MSTN) gene affects carcass conformation and fatness in the Norwegian Spaelsau (Ovis aries).","date":"2009","source":"BMC research notes","url":"https://pubmed.ncbi.nlm.nih.gov/19505313","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28708509","id":"PMC_28708509","title":"GDF8 activates p38 MAPK signaling during porcine oocyte maturation in vitro.","date":"2017","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/28708509","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32165710","id":"PMC_32165710","title":"Exogenous GDF11, but not GDF8, reduces body weight and improves glucose homeostasis in mice.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32165710","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24197697","id":"PMC_24197697","title":"Targeted disruption of the sheep MSTN gene by engineered zinc-finger nucleases.","date":"2013","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24197697","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21743995","id":"PMC_21743995","title":"A promoter polymorphism of MSTN g.-371T>A and its associations with carcass traits in Korean cattle.","date":"2011","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21743995","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31414284","id":"PMC_31414284","title":"Inhibition of MSTN signal pathway may participate in LIPUS preventing bone loss in ovariectomized rats.","date":"2019","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/31414284","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30604488","id":"PMC_30604488","title":"The contribution of myostatin (MSTN) and additional modifying genetic loci to race distance aptitude in Thoroughbred horses racing in different geographic regions.","date":"2019","source":"Equine veterinary journal","url":"https://pubmed.ncbi.nlm.nih.gov/30604488","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33195207","id":"PMC_33195207","title":"GDF8 Promotes the Cell Invasiveness in Human Trophoblasts by Upregulating the Expression of Follistatin-Like 3 Through the ALK5-SMAD2/3 Signaling Pathway.","date":"2020","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/33195207","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36037573","id":"PMC_36037573","title":"Germline transmission of MSTN knockout cattle via CRISPR-Cas9.","date":"2022","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/36037573","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31906236","id":"PMC_31906236","title":"Growth Differentiation Factor-8 (GDF8)/Myostatin is a Predictor of Troponin I Peak and a Marker of Clinical Severity after Acute Myocardial Infarction.","date":"2019","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31906236","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23613242","id":"PMC_23613242","title":"Polymorphisms of the myostatin gene (MSTN) and its relationship with growth traits in goat breeds.","date":"2013","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/23613242","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29156385","id":"PMC_29156385","title":"Interaction with the GDF8/11 pathway reveals treatment options for adenocarcinoma of the breast.","date":"2017","source":"Breast (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/29156385","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32156541","id":"PMC_32156541","title":"Mutation in myostatin 3'UTR promotes C2C12 myoblast proliferation and differentiation by blocking the translation of MSTN.","date":"2020","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/32156541","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18389502","id":"PMC_18389502","title":"Mammary gland differentiation inversely correlates with GDF-8 expression.","date":"2008","source":"Molecular reproduction and development","url":"https://pubmed.ncbi.nlm.nih.gov/18389502","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31265735","id":"PMC_31265735","title":"Expression of MSTN gene and its correlation with pectoralis muscle fiber traits in the domestic pigeons (Columba livia).","date":"2019","source":"Poultry science","url":"https://pubmed.ncbi.nlm.nih.gov/31265735","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39365728","id":"PMC_39365728","title":"A MSTNDel73C mutation with FGF5 knockout sheep by CRISPR/Cas9 promotes skeletal muscle myofiber hyperplasia.","date":"2024","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/39365728","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34432647","id":"PMC_34432647","title":"GDF-8 stimulates trophoblast cell invasion by inducing ALK5-SMAD2/3-mediated MMP2 expression.","date":"2021","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/34432647","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24081623","id":"PMC_24081623","title":"Genetic variations in the myostatin gene (MSTN) in New Zealand sheep breeds.","date":"2013","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24081623","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19533681","id":"PMC_19533681","title":"Characterization of myostatin/gdf8/11 in the starlet sea anemone Nematostella vectensis.","date":"2009","source":"Journal of experimental zoology. Part B, Molecular and developmental evolution","url":"https://pubmed.ncbi.nlm.nih.gov/19533681","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26846723","id":"PMC_26846723","title":"Quantitative measurements of GDF-8 using immunoaffinity LC-MS/MS.","date":"2016","source":"Proteomics. Clinical applications","url":"https://pubmed.ncbi.nlm.nih.gov/26846723","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30814254","id":"PMC_30814254","title":"Crystal structure of the WFIKKN2 follistatin domain reveals insight into how it inhibits growth differentiation factor 8 (GDF8) and GDF11.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30814254","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22666112","id":"PMC_22666112","title":"Assessment of tools for marker-assisted selection in a marine commercial species: significant association between MSTN-1 gene polymorphism and growth traits.","date":"2012","source":"TheScientificWorldJournal","url":"https://pubmed.ncbi.nlm.nih.gov/22666112","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28506172","id":"PMC_28506172","title":"The Effect of Myostatin (GDF-8) on Proliferation and Tenocyte Differentiation of Rat Bone Marrow-Derived Mesenchymal Stem Cells.","date":"2017","source":"The journal of hand surgery Asian-Pacific volume","url":"https://pubmed.ncbi.nlm.nih.gov/28506172","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30267811","id":"PMC_30267811","title":"Effects of fasting and re-feeding on mstn and mstnb genes expressions in Cranoglanis bouderius.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30267811","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30825707","id":"PMC_30825707","title":"GDF8 enhances SOX2 expression and blastocyst total cell number in porcine IVF embryo development.","date":"2019","source":"Theriogenology","url":"https://pubmed.ncbi.nlm.nih.gov/30825707","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25048241","id":"PMC_25048241","title":"A prepared anti-MSTN polyclonal antibody reverses insulin resistance of diet-induced obese rats via regulation of PI3K/Akt/mTOR&FoxO1 signal pathways.","date":"2014","source":"Biotechnology letters","url":"https://pubmed.ncbi.nlm.nih.gov/25048241","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24796976","id":"PMC_24796976","title":"A new single nucleotide polymorphism in the rabbit (Oryctolagus cuniculus) myostatin (MSTN) gene is associated with carcass composition traits.","date":"2014","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24796976","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31073529","id":"PMC_31073529","title":"Label-Free LC-MS/MS Proteomics Analyses Reveal Proteomic Changes Accompanying MSTN KO in C2C12 Cells.","date":"2019","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/31073529","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18563849","id":"PMC_18563849","title":"A retrovirus-based system to stably silence GDF-8 expression and enhance myogenic differentiation in human rhabdomyosarcoma cells.","date":"2008","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18563849","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25273961","id":"PMC_25273961","title":"Analysis of the 227 bp short interspersed nuclear element (SINE) insertion of the promoter of the myostatin (MSTN) gene in different horse breeds.","date":"2014","source":"Veterinaria italiana","url":"https://pubmed.ncbi.nlm.nih.gov/25273961","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12212941","id":"PMC_12212941","title":"Identification of three SNPs in the porcine myostatin gene (MSTN).","date":"2002","source":"Animal biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/12212941","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36292721","id":"PMC_36292721","title":"MSTN Regulatory Network in Mongolian Horse Muscle Satellite Cells Revealed with miRNA Interference Technologies.","date":"2022","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36292721","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37709247","id":"PMC_37709247","title":"Resistance exercise alleviates dexamethasone-induced muscle atrophy via Sestrin2/MSTN pathway in C57BL/6J mice.","date":"2023","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/37709247","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23479163","id":"PMC_23479163","title":"Characterization of myostatin gene (MSTN) of Pekin duck and the association of its polymorphism with breast muscle traits.","date":"2013","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/23479163","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33846367","id":"PMC_33846367","title":"A highly prevalent SINE mutation in the myostatin (MSTN) gene promoter is associated with low circulating myostatin concentration in Thoroughbred racehorses.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33846367","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34239360","id":"PMC_34239360","title":"High ovarian GDF-8 levels contribute to elevated estradiol production in ovarian hyperstimulation syndrome by stimulating aromatase expression.","date":"2021","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34239360","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31638376","id":"PMC_31638376","title":"Targeting Unique Epitopes on Highly Similar Proteins GDF-11 and GDF-8 with Modified DNA Aptamers.","date":"2019","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31638376","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31302418","id":"PMC_31302418","title":"Significant body mass increase by oral administration of a cascade of shIL21-MSTN yeast-based DNA vaccine in mice.","date":"2019","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/31302418","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31486116","id":"PMC_31486116","title":"Increasing the accuracy of genomic prediction in pure-bred Limousin beef cattle by including cross-bred Limousin data and accounting for an F94L variant in MSTN.","date":"2019","source":"Animal genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31486116","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35268106","id":"PMC_35268106","title":"Differential Expression of MSTN Isoforms in Muscle between Broiler and Layer Chickens.","date":"2022","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/35268106","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24299184","id":"PMC_24299184","title":"Characterization of 5' upstream region and investigation of TTTTA deletion in 5' UTR of myostatin (MSTN) gene in Indian goat breeds.","date":"2014","source":"Animal biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/24299184","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33876824","id":"PMC_33876824","title":"Characterization of tolloid-mediated cleavage of the GDF8 procomplex.","date":"2021","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/33876824","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9139826","id":"PMC_9139826","title":"Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member.","date":"1997","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9139826","citation_count":3085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9356471","id":"PMC_9356471","title":"Double muscling in cattle due to mutations in the myostatin gene.","date":"1997","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9356471","citation_count":1400,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11459935","id":"PMC_11459935","title":"Regulation of myostatin activity and muscle growth.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11459935","citation_count":1239,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9288100","id":"PMC_9288100","title":"A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle.","date":"1997","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9288100","citation_count":1036,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15215484","id":"PMC_15215484","title":"Myostatin mutation associated with gross muscle hypertrophy in a child.","date":"2004","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/15215484","citation_count":1019,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19357233","id":"PMC_19357233","title":"Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size.","date":"2009","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/19357233","citation_count":600,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14517293","id":"PMC_14517293","title":"Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14517293","citation_count":450,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9843994","id":"PMC_9843994","title":"Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9843994","citation_count":437,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22020285","id":"PMC_22020285","title":"Image-based genome-wide siRNA screen identifies selective autophagy factors.","date":"2011","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/22020285","citation_count":405,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17823296","id":"PMC_17823296","title":"Time course of proteolytic, cytokine, and myostatin gene expression after acute exercise in human skeletal muscle.","date":"2007","source":"Journal of applied physiology (Bethesda, Md. : 1985)","url":"https://pubmed.ncbi.nlm.nih.gov/17823296","citation_count":371,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12194980","id":"PMC_12194980","title":"The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12194980","citation_count":368,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10844590","id":"PMC_10844590","title":"The family of bone morphogenetic proteins.","date":"2000","source":"Kidney international","url":"https://pubmed.ncbi.nlm.nih.gov/10844590","citation_count":353,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21900845","id":"PMC_21900845","title":"Strength training with blood flow restriction diminishes myostatin gene expression.","date":"2012","source":"Medicine and science in sports and exercise","url":"https://pubmed.ncbi.nlm.nih.gov/21900845","citation_count":319,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10362012","id":"PMC_10362012","title":"Myostatin, a transforming growth factor-beta superfamily member, is expressed in heart muscle and is upregulated in cardiomyocytes after infarct.","date":"1999","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/10362012","citation_count":314,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8622651","id":"PMC_8622651","title":"Activation of signalling by the activin receptor complex.","date":"1996","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8622651","citation_count":296,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18835929","id":"PMC_18835929","title":"Increased secretion and expression of myostatin in skeletal muscle from extremely obese women.","date":"2008","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/18835929","citation_count":252,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7558031","id":"PMC_7558031","title":"Comparative genome map of human and cattle.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7558031","citation_count":244,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24145431","id":"PMC_24145431","title":"Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24145431","citation_count":229,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18240972","id":"PMC_18240972","title":"Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation.","date":"2008","source":"Rejuvenation research","url":"https://pubmed.ncbi.nlm.nih.gov/18240972","citation_count":219,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10508689","id":"PMC_10508689","title":"Myostatin and the control of skeletal muscle mass.","date":"1999","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/10508689","citation_count":208,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27304512","id":"PMC_27304512","title":"Quantification of GDF11 and Myostatin in Human Aging and Cardiovascular Disease.","date":"2016","source":"Cell metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/27304512","citation_count":176,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12595574","id":"PMC_12595574","title":"Regulation of myostatin in vivo by growth and differentiation factor-associated serum protein-1: a novel protein with protease inhibitor and follistatin domains.","date":"2003","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12595574","citation_count":174,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27034275","id":"PMC_27034275","title":"Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation.","date":"2016","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/27034275","citation_count":169,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28627027","id":"PMC_28627027","title":"Elevated serum myostatin level is associated with worse survival in patients with liver cirrhosis.","date":"2017","source":"Journal of cachexia, sarcopenia and muscle","url":"https://pubmed.ncbi.nlm.nih.gov/28627027","citation_count":159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24457615","id":"PMC_24457615","title":"Myostatin and sarcopenia: opportunities and challenges - a mini-review.","date":"2014","source":"Gerontology","url":"https://pubmed.ncbi.nlm.nih.gov/24457615","citation_count":150,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17609255","id":"PMC_17609255","title":"Smoking impairs muscle protein synthesis and increases the expression of myostatin and MAFbx in muscle.","date":"2007","source":"American journal of physiology. Endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17609255","citation_count":139,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50203,"output_tokens":5121,"usd":0.113712},"stage2":{"model":"claude-opus-4-6","input_tokens":8649,"output_tokens":3668,"usd":0.202418},"total_usd":0.671773,"stage1_batch_id":"msgbatch_01Mgbec4vM6c9vXht7JVJzss","stage2_batch_id":"msgbatch_01JkuuH5RB2BdJNsgnhjbC6s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":63840,"output_tokens":7251,"usd":0.150143},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11240,"output_tokens":3232,"usd":0.2055}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Loss-of-function mutations in myostatin (GDF8) cause double-muscling in cattle: an 11-bp deletion in Belgian Blue removes the conserved C-terminal TGF-β domain, while a C→Y missense in Piedmontese disrupts a hallmark cysteine residue, establishing myostatin as a negative regulator of muscle mass.\",\n      \"method\": \"Sequence analysis of bovine myostatin cDNA and genomic DNA in normal vs. double-muscled cattle; comparison with mouse targeted disruption phenotype\",\n      \"journal\": \"Genome research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — replicated across two independent cattle breeds with distinct loss-of-function alleles; consistent with prior mouse KO phenotype\",\n      \"pmids\": [\"9314496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The GDF-8 (myostatin) propeptide forms a noncovalent inhibitory complex with mature GDF-8, blocks GDF-8 binding to L6 myoblast cell-surface receptors, and suppresses GDF-8-induced reporter activity in A204 cells, identifying the propeptide as an endogenous antagonist.\",\n      \"method\": \"Size exclusion chromatography, chemical crosslinking, cell-based (CAGA)12 reporter assay, competitive receptor-binding assay on L6 myoblasts\",\n      \"journal\": \"Growth factors (Chur, Switzerland)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal in vitro methods (chromatography, crosslinking, cell reporter, binding assay) in a single study\",\n      \"pmids\": [\"11519824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"GDF-8 (myostatin) suppresses proliferation of porcine embryonic myogenic cells, and this effect is partially mediated by IGFBP-3: GDF-8 treatment increases IGFBP-3 mRNA and protein, and neutralizing IGFBP-3 antibody reduces the anti-proliferative effect of GDF-8 alone.\",\n      \"method\": \"PEMC cell culture proliferation assays, western blot and RT-PCR for IGFBP-3, antibody neutralization experiments\",\n      \"journal\": \"Journal of cellular physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods in single lab; mechanistic link between GDF-8 signaling and IGFBP-3 induction established\",\n      \"pmids\": [\"14502562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) in a load-dependent manner; the type IIB activin receptor (AcvrIIB) is expressed on BMSCs, and recombinant myostatin treatment suppresses BMP-2 and IGF-1 expression during mechanical stimulation.\",\n      \"method\": \"Immunofluorescence for AcvrIIB in BMSCs, in vitro osteogenic differentiation assays comparing myostatin-deficient vs. WT BMSCs, recombinant myostatin treatment, hindlimb unloading model\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO combined with receptor localization and recombinant protein treatment; single lab\",\n      \"pmids\": [\"17383950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Myostatin (GDF-8) directly inhibits chondrogenesis: treatment with recombinant myostatin suppresses Sox9 mRNA expression and collagen type II protein synthesis in BMSCs, and myostatin deficiency increases proliferation of epiphyseal growth plate chondrocytes.\",\n      \"method\": \"In vitro chondrogenic differentiation assays, real-time PCR for Sox9, western blot for collagen type II, proliferation assays in myostatin-deficient vs. WT cells\",\n      \"journal\": \"Growth factors (Chur, Switzerland)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — recombinant protein treatment plus KO comparison, multiple readouts; single lab\",\n      \"pmids\": [\"21756198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Small molecule kinase inhibitors dorsomorphin and LDN-193189 inhibit GDF8/myostatin-induced SMAD2/3 signaling by targeting type I receptor activity, rescue myogenic transcription factor expression, and promote contractile myotube network formation in vitro; crystal structure of ActRIIA with dorsomorphin was resolved.\",\n      \"method\": \"Crystal structure (ActRIIA:dorsomorphin), cell-based SMAD2/3 phosphorylation assays, myoblast differentiation assays, quantitative live-cell microscopy of myotube contraction\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus functional in vitro assays with mutagenesis context; multiple orthogonal methods\",\n      \"pmids\": [\"25368322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Crystal structures of apo-GDF8, apo-GDF11, and the GDF11:FS288 complex reveal that GDF11 has unique structural features in the type I receptor binding site conferring greater potency; substituting GDF11 residues into GDF8 enhances GDF8 SMAD2/3 signaling activity, and GDF11 signals more potently through ALK4/5/7 than GDF8.\",\n      \"method\": \"Crystal structure determination (apo-GDF8, apo-GDF11, GDF11:FS288), cell-based SMAD2/3 reporter assays, chimeric ligand mutagenesis\",\n      \"journal\": \"BMC biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple crystal structures plus functional validation by mutagenesis and cell-based signaling assays\",\n      \"pmids\": [\"28257634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"GDF8 (myostatin) inhibits osteoblast differentiation and promotes RANKL-induced osteoclastogenesis in primary mouse osteoblast cultures; intraperitoneal injection of recombinant GDF8 in mice represses bone formation and accelerates bone resorption, while a neutralizing antibody stimulates bone formation.\",\n      \"method\": \"In vitro osteoblast and osteoclast differentiation assays, in vivo recombinant GDF8 injection, in vivo neutralizing antibody treatment with histomorphometric analysis\",\n      \"journal\": \"Clinical and experimental pharmacology & physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro and in vivo experiments with both gain-of-function and loss-of-function approaches; single lab\",\n      \"pmids\": [\"28074479\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Crystal structure of the WFIKKN2 follistatin domain (FSD) at 1.39 Å reveals that it binds GDF8 and GDF11 and blocks their interaction with ActRIIB; surface-exposed residues identified by alanine-scanning mutagenesis are required for GDF8 antagonism, and the binding mode differs from follistatin and FSTL3 FSDs.\",\n      \"method\": \"Crystal structure at 1.39 Å, native gel shift, surface plasmon resonance, alanine-scanning mutagenesis, cell-based antagonism assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure plus SPR binding and functional mutagenesis\",\n      \"pmids\": [\"30814254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GDF8 upregulates SERPINE1 expression in human granulosa-lutein cells via the ALK5-SMAD2/3-SMAD4 signaling pathway (not ERK1/2), and SERPINE1 mediates GDF8-induced impairment of glucose metabolism; TP53 is required for GDF8-stimulated SERPINE1 upregulation.\",\n      \"method\": \"Transcriptome sequencing, siRNA knockdown of ALK5/SMAD2/3/SMAD4/TP53, pharmacological inhibition (SB-431542), western blot for pathway components, glucose metabolism assays\",\n      \"journal\": \"Molecular therapy. Nucleic acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissected with multiple siRNA knockdowns and pharmacological inhibition; single lab\",\n      \"pmids\": [\"33425488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Myostatin (MSTN) attenuates pathological cardiac hypertrophy by inhibiting excessive autophagy via direct inactivation of AMPK/mTOR and activation of PPARγ/NF-κB signaling; MSTN also downregulates miR-128, which otherwise suppresses PPARγ to promote hypertrophy.\",\n      \"method\": \"In vivo aortic coarctation and Ang II models in MSTN-deficient mice, in vitro cardiomyocyte assays, western blot for AMPK/mTOR/PPARγ/NF-κB pathway components, miR-128 manipulation\",\n      \"journal\": \"Molecular therapy. Nucleic acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KO and in vitro experiments with multiple pathway readouts; single lab\",\n      \"pmids\": [\"31923740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"MSTN mutation (loss-of-function) promotes myogenic differentiation by increasing expression of demethylase TET1; ChIP-qPCR demonstrates that the SMAD2/SMAD3 complex binds directly to the TET1 promoter to inhibit its activity, linking MSTN signaling to epigenetic regulation of myogenesis-specific gene methylation.\",\n      \"method\": \"ChIP-qPCR, bisulfite sequencing for promoter methylation, RT-PCR, western blot, myotube fusion assay, TET1 overexpression and knockdown in satellite cells\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-qPCR directly demonstrates SMAD2/3 binding to TET1 promoter; supported by functional gain/loss-of-function; single lab\",\n      \"pmids\": [\"32210722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GDF11 promotes osteogenesis whereas MSTN inhibits it; Mstn deletion upregulates Gdf11 expression, which activates BMP signaling to enhance osteoblast and chondrocyte maturation; mice overexpressing follistatin (inhibiting both MSTN and GDF11) develop bone fractures not seen in Mstn null mice, demonstrating that GDF11 inhibition impairs bone strength.\",\n      \"method\": \"Genetic studies using Gdf11 and Mstn null mice, Gdf11/Mstn double null, follistatin-overexpressing mice; osteoblast and chondrocyte differentiation assays, BMP signaling pathway analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models with clear epistasis logic; strong evidence distinguishing MSTN from GDF11 functions using genetic approaches\",\n      \"pmids\": [\"32071240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GDF8 activates p38 MAPK signaling during porcine oocyte maturation via ActRIIb and Alk4/5 type receptors; activated p38 MAPK alters expression of Nrf2 and Bcl-2 in oocytes and cumulus expansion genes (Has2, Ptx3, TNFAIP6) in cumulus cells, reducing intracellular ROS and improving embryonic developmental competence.\",\n      \"method\": \"In vitro maturation assays with recombinant GDF8, RT-PCR for receptor and target genes, western blot for p38 MAPK phosphorylation, ROS measurement, IVF and parthenogenetic activation embryo development\",\n      \"journal\": \"Theriogenology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor gene induction and downstream phosphorylation directly measured; functional readout via embryo development; single lab\",\n      \"pmids\": [\"28708509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GDF8 promotes trophoblast cell invasiveness by upregulating follistatin-like 3 (FSTL3) expression via the ALK5-SMAD2/3 signaling pathway, as demonstrated by siRNA-mediated knockdown of pathway components.\",\n      \"method\": \"siRNA knockdown of ALK5, SMAD2, SMAD3 in immortalized and primary EVT cells, FSTL3 protein/mRNA measurement, Matrigel invasion assay\",\n      \"journal\": \"Frontiers in cell and developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissected with multiple siRNA knockdowns; two cell models; single lab\",\n      \"pmids\": [\"33195207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GDF-8 stimulates trophoblast cell invasion by upregulating MMP2 (but not MMP9) expression through the ALK5-SMAD2/3 signaling pathway; knockdown of MMP2 attenuates GDF-8-induced invasiveness.\",\n      \"method\": \"siRNA knockdown of ALK5, SMAD2, SMAD3, MMP2 in HTR-8/SVneo cells; Matrigel invasion assay; western blot and RT-PCR for MMP2/MMP9\",\n      \"journal\": \"Reproduction (Cambridge, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pathway dissected with multiple siRNA knockdowns and functional invasion readout; single lab\",\n      \"pmids\": [\"34432647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Tolloid metalloprotease activates latent GDF8 by cleaving the prodomain at D99; alanine mutagenesis identifies residues Y94 and D92 near the scissile bond as critical for tolloid recognition—mutation of these residues abolishes proteolytic activation, while acidic conditions can bypass this requirement; prodomain mutants co-expressed with WT GDF8 act as dominant negatives.\",\n      \"method\": \"Sequential alanine mutagenesis of GDF8 prodomain, in vitro tolloid cleavage assay using Tll1 astacin domain, purified latent complex activation assays, co-expression dominant negative experiments\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro proteolysis assay with systematic mutagenesis identifying specific catalytic determinants\",\n      \"pmids\": [\"33876824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"A SINE insertion in the equine MSTN gene promoter is associated with significantly lower circulating serum myostatin concentrations in a dose-dependent manner (homozygotes < heterozygotes < wild-type), directly demonstrating in vivo functional consequence of this promoter variant on protein expression.\",\n      \"method\": \"PCR genotyping of SINE insertion, validated ELISA for serum myostatin in 176 Thoroughbred horses under identical management\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct quantitative measurement of protein levels linked to genotype in a large, controlled cohort; single study\",\n      \"pmids\": [\"33846367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GDF-8 stimulates aromatase (CYP19A1) expression and estradiol production in human granulosa cells via ALK5-mediated SMAD2/3 signaling; blocking ALK5 with SB431542 in a rat OHSS model alleviates OHSS symptoms and attenuates upregulation of aromatase.\",\n      \"method\": \"siRNA knockdown of ALK5/SMAD2/SMAD3 in hGL and KGN cells, pharmacological inhibition (SB431542), rat OHSS model, ELISA for follicular fluid GDF-8, aromatase mRNA/protein measurement, E2 production assay\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple siRNA knockdowns and in vivo pharmacological rescue; single lab\",\n      \"pmids\": [\"34239360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"GDF8 (myostatin) and activin A are identified as the two major ActRIIA/B ligands responsible for muscle minimization; dual blockade of GDF8 and activin A prevents GLP-1 receptor agonist-induced muscle loss and promotes muscle mass gain while enhancing fat loss in obese mice and non-human primates.\",\n      \"method\": \"Dual antibody blockade of GDF8 and activin A in diet-induced obese mice and non-human primates on GLP-1 agonist treatment; body composition, muscle mass, and fat mass measurements\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo experiments in two mammalian models with dual blockade identifying specific ligands; single lab study\",\n      \"pmids\": [\"40360507\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Myostatin (GDF8/MSTN) is synthesized as a latent complex held inactive by noncovalent association of its prodomain with the mature C-terminal dimer; tolloid metalloproteases activate it by cleaving the prodomain at D99 (requiring residues Y94/D92), whereupon the active ligand signals through type II receptors ActRIIA/B and type I receptors ALK4/5 to phosphorylate SMAD2/3, which suppresses muscle satellite cell proliferation and differentiation, activates IGFBP-3-dependent anti-proliferative mechanisms, and regulates downstream targets including TET1 (via SMAD2/3 promoter binding), MMP2, FSTL3, SERPINE1, and AMPK/mTOR/PPARγ pathways; extracellularly it is inhibited by its own propeptide, follistatin, FSTL3, and WFIKKN2 (all blocking ActRIIB binding), and in addition to muscle it directly suppresses osteoblast differentiation while promoting osteoclastogenesis, inhibits chondrogenesis via Sox9 suppression, and regulates cardiac autophagy and reproductive cell functions.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"GDF-8 (myostatin) is expressed specifically in developing and adult skeletal muscle; targeted disruption in mice causes a large and widespread increase in skeletal muscle mass (2–3× per muscle), resulting from both muscle cell hyperplasia and hypertrophy, establishing myostatin as a negative regulator of skeletal muscle growth.\",\n      \"method\": \"Gene targeting / knockout mouse, muscle weight measurements, histology\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original knockout study, widely replicated across species\",\n      \"pmids\": [\"9139826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Loss-of-function mutations in the myostatin coding sequence (11-bp deletion causing frameshift in Belgian Blue; C→Y missense in conserved cysteine in Piedmontese) underlie the double-muscled phenotype in cattle, confirming myostatin as a negative regulator of muscle mass in cattle.\",\n      \"method\": \"cDNA cloning, sequence analysis of normal and double-muscled cattle, expression profiling\",\n      \"journal\": \"Genome research / PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct mutation identification confirmed by two independent groups in two breeds\",\n      \"pmids\": [\"9314496\", \"9356471\", \"9288100\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Mature myostatin protein consists of a noncovalently held complex of the N-terminal propeptide and a disulfide-linked C-terminal dimer; the C-terminal dimer binds the activin type II receptors ActRIIB (high affinity) and ActRIIA (lower affinity). Transgenic overexpression of the propeptide, follistatin, or a dominant-negative ActRIIB in skeletal muscle each produce dramatic muscle mass increases comparable to myostatin knockouts, establishing these as functional inhibitors of the pathway in vivo.\",\n      \"method\": \"Protein purification from mammalian cells, receptor binding assays, transgenic mouse overexpression with muscle mass phenotyping\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical characterization plus in vivo genetic epistasis, foundational study\",\n      \"pmids\": [\"11459935\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"The GDF-8 propeptide forms a noncovalent complex with mature GDF-8 (shown by size exclusion chromatography and chemical crosslinking), inhibits GDF-8 biological activity in a reporter-gene assay, and blocks specific GDF-8 binding to L6 myoblast cells, identifying the propeptide as a direct inhibitor that acts by preventing receptor binding.\",\n      \"method\": \"Size exclusion chromatography, chemical crosslinking, cell-based reporter assay, radioligand receptor-binding competition\",\n      \"journal\": \"Growth factors\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal in vitro methods in single study\",\n      \"pmids\": [\"11519824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Circulating myostatin in normal mouse and human serum is bound in latent complexes with at least two major inhibitory proteins: the myostatin propeptide (accounting for >70% of serum myostatin) and the follistatin-related gene product FLRG. FLRG was confirmed to bind mature myostatin directly and inhibit its activity in a reporter assay.\",\n      \"method\": \"Affinity purification with anti-myostatin monoclonal antibody, mass spectrometry, Western blot, recombinant protein binding, luciferase reporter assay\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — immunoprecipitation/MS identification plus functional validation, in vivo relevance confirmed\",\n      \"pmids\": [\"12194980\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Myostatin signals via ActRIIB as the primary type II receptor, then partners with ALK4 (ActRIB) or ALK5 (TβRI) as type I receptors to phosphorylate Smad2/Smad3, activating a TGF-β-like pathway. Myostatin inhibits BMP7- but not BMP2-mediated adipogenic differentiation by competing for ActRIIB, thereby blocking adipogenesis.\",\n      \"method\": \"Receptor binding assays, reporter gene assays, co-immunoprecipitation, siRNA knockdown, BMP competition binding\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — receptor characterization with multiple orthogonal methods plus functional pathway dissection\",\n      \"pmids\": [\"14517293\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"GASP-1 (growth and differentiation factor-associated serum protein-1), containing whey acidic protein, Kazal, two Kunitz, netrin, and follistatin-like domains, is identified as an endogenous serum-binding protein of myostatin. GASP-1 binds both mature myostatin and the myostatin propeptide directly and inhibits mature myostatin biological activity but not activin activity.\",\n      \"method\": \"Affinity purification from serum, mass spectrometry, recombinant protein binding, luciferase reporter assay\",\n      \"journal\": \"Molecular Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — endogenous complex identified by MS, binding and function confirmed with recombinant proteins\",\n      \"pmids\": [\"12595574\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"GDF-8 treatment of porcine embryonic myogenic cells suppresses proliferation and increases IGFBP-3 protein and mRNA production; a neutralizing anti-IGFBP-3 antibody partially rescues GDF-8-induced proliferation suppression, indicating IGFBP-3 mediates part of GDF-8's anti-proliferative effect in myogenic cells.\",\n      \"method\": \"Cell proliferation assay, ELISA/immunoblot for IGFBP-3, antibody neutralization\",\n      \"journal\": \"Journal of Cellular Physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — functional antibody rescue confirms mechanistic role, single lab\",\n      \"pmids\": [\"14502562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"A child with exceptional muscle hypertrophy was found to carry a mutation in the human MSTN gene, demonstrating that myostatin regulates muscle mass in humans.\",\n      \"method\": \"Clinical genetics, sequencing of human MSTN gene in patient\",\n      \"journal\": \"New England Journal of Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function human mutation with defined phenotypic readout; landmark human validation\",\n      \"pmids\": [\"15215484\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Myostatin inhibits activation of the Akt/mTOR/p70S6K protein synthesis pathway in myoblasts and myotubes, requiring Smad2 and Smad3 downstream of ActRII/ALK receptors. Blockade of RAPTOR (TORC1 component) amplifies myostatin-induced Smad2 phosphorylation, establishing a cross-talk whereby Akt suppression by myostatin feeds back to enhance Smad signaling. Myostatin decreases myotube diameter without upregulating atrophy E3 ligases MuRF1/MAFbx, instead suppressing differentiation-associated genes.\",\n      \"method\": \"siRNA knockdown of RAPTOR/RICTOR, phospho-protein immunoblot, myotube diameter measurement, gene expression\",\n      \"journal\": \"American Journal of Physiology – Cell Physiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mechanistic dissection with siRNA epistasis and multiple pathway readouts, widely cited\",\n      \"pmids\": [\"19357233\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The human myostatin gene comprises three exons and two introns, maps to chromosomal region 2q33.2, is transcribed as a 3.1-kb mRNA encoding a 375-aa precursor protein, and is expressed in skeletal muscle as a secreted 26-kDa mature glycoprotein detectable in plasma. Serum and intramuscular myostatin concentrations are elevated in HIV-infected men with weight loss and correlate inversely with fat-free mass, implicating myostatin in human muscle wasting.\",\n      \"method\": \"Molecular cloning, RT-PCR, Western blot, immunohistochemistry, ELISA\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gene structure characterized, protein detected in plasma with functional context\",\n      \"pmids\": [\"9843994\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Myostatin mRNA and protein are expressed not only in skeletal muscle but also in fetal and adult heart tissue, with protein localized to Purkinje fibers and cardiomyocytes; myostatin expression is upregulated in cardiomyocytes surrounding the infarct zone after myocardial infarction, suggesting a role in cardiac physiology.\",\n      \"method\": \"RT-PCR, Western blot, immunohistochemistry on heart sections, myocardial infarction model\",\n      \"journal\": \"Journal of Cellular Physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization and regulated expression in cardiac tissue with disease model\",\n      \"pmids\": [\"10362012\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Hyperammonemia (as occurs in liver cirrhosis) induces myostatin expression in skeletal muscle via an NF-κB-dependent mechanism: ammonia activates IκB kinase, triggers NF-κB nuclear translocation, and the NF-κB p65 subunit binds specific sites in the myostatin promoter to drive transcription. Pharmacologic inhibition or gene silencing of NF-κB abolishes this upregulation.\",\n      \"method\": \"C2C12 myotube ammonium acetate treatment, NF-κB ChIP, siRNA knockdown, IKK inhibitor, primary muscle cell cultures, in vivo mouse hyperammonemia model\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP identifies direct promoter binding, confirmed by siRNA and pharmacological inhibition in vitro and in vivo\",\n      \"pmids\": [\"24145431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Despite 90% amino acid sequence identity, GDF11 is a more potent activator of SMAD2/3 and signals more effectively through ALK4/5/7 than GDF8. Crystal structures of the GDF11:FS288 complex, apo-GDF8, and apo-GDF11 reveal unique structural features in the type I receptor binding site of each ligand; substitution of GDF11 residues into GDF8 confers enhanced SMAD2/3 signaling activity to GDF8.\",\n      \"method\": \"Crystal structure determination, SMAD2/3 phosphorylation assays, chimeric protein mutagenesis, receptor signaling assays\",\n      \"journal\": \"BMC Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structures plus mutagenesis and functional validation in single study\",\n      \"pmids\": [\"28257634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"The WFIKKN2 follistatin domain (FSD) directly binds GDF8 and GDF11 and blocks their interaction with the type II receptor ActRIIB (shown by native gel shift and surface plasmon resonance). Crystal structure of the WFIKKN2 FSD at 1.39 Å identified surface-exposed residues that, when mutated to alanine, reduce GDF8 antagonism in full-length WFIKKN2. The WFIKKN2 FSD inhibits GDF8 via different binding contacts than follistatin or FSTL3.\",\n      \"method\": \"Protein crystallography (1.39 Å), surface plasmon resonance, native gel shift, alanine-scanning mutagenesis, functional antagonism assay\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mutagenesis and SPR binding validation\",\n      \"pmids\": [\"30814254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Tolloid-family metalloproteases activate latent GDF8 by cleaving the prodomain at residue D99. Sequential alanine mutagenesis identified Y94 and D92 as critical residues adjacent to the scissile bond for tolloid recognition; D92A and Y94A mutations impede tolloid-mediated cleavage but allow full activation under acidic conditions. Co-expression of tolloid-resistant prodomain mutants with wild-type GDF8 suppresses GDF8 activity in a dominant-negative manner.\",\n      \"method\": \"Alanine-scanning mutagenesis of GDF8 prodomain, in vitro protease cleavage assays using astacin domain of Tll1, latent complex purification, reporter assay\",\n      \"journal\": \"Biochemical Journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro cleavage assay with mutagenesis identifies specific recognition residues\",\n      \"pmids\": [\"33876824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The small molecules dorsomorphin and LDN-193189 inhibit GDF8/myostatin signaling by binding the type II receptor ActRIIA (crystal structure of ActRIIA:dorsomorphin solved), blocking GDF8-induced Smad2/3 phosphorylation and repression of myogenic transcription factors, thereby rescuing myoblast differentiation and promoting contractile myotubular network activity.\",\n      \"method\": \"Crystal structure determination of ActRIIA:dorsomorphin, Smad2/3 phosphorylation assays, myoblast differentiation assays, quantitative live-cell microscopy\",\n      \"journal\": \"Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure plus functional assays with mechanistic pathway readout\",\n      \"pmids\": [\"25368322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In MSTN mutant (MSTN-/+) satellite cells, SMAD2/SMAD3 complex binding to the TET1 promoter normally represses TET1 transcription. Loss of MSTN signaling reduces SMAD2/SMAD3 occupancy at the TET1 promoter (shown by ChIP-qPCR), increasing TET1 demethylase expression and reducing DNA methylation of PAX3, PAX7, MyoD, and MyoG promoters/gene bodies, thereby promoting myogenic differentiation.\",\n      \"method\": \"ChIP-qPCR, bisulfite sequencing (methylation analysis), TET1 overexpression and knockdown, myotube fusion index\",\n      \"journal\": \"International Journal of Biological Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP-qPCR directly demonstrates SMAD2/3 binding to TET1 promoter; single lab\",\n      \"pmids\": [\"32210722\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GDF8 upregulates SERPINE1 (PAI-1) expression in human granulosa-lutein cells via the ALK5-mediated SMAD2/3-SMAD4 signaling pathway (not via ERK1/2, which is also activated but is not required for SERPINE1 induction), and requires TP53; this SERPINE1 upregulation mediates GDF8-induced glucose metabolism defects.\",\n      \"method\": \"siRNA knockdown of ALK5, SMAD2, SMAD3, ERK1/2, TP53; pharmacological inhibitor SB-431542; transcriptome sequencing; DHEA-induced PCOS mouse model\",\n      \"journal\": \"Molecular Therapy – Nucleic Acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple siRNA and pharmacological approaches dissect the pathway; single lab\",\n      \"pmids\": [\"33425488\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"GDF8 upregulates FSTL3 expression in human extravillous cytotrophoblast cells via the ALK5-SMAD2/3 signaling pathway, and this FSTL3 induction promotes trophoblast cell invasiveness; siRNA knockdown of ALK5 or SMAD2/3 abolishes the effect.\",\n      \"method\": \"siRNA knockdown, immunoblot, invasion assay (Matrigel), pharmacological inhibitor\",\n      \"journal\": \"Frontiers in Cell and Developmental Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA epistasis identifies the ALK5-SMAD2/3 pathway; single lab\",\n      \"pmids\": [\"33195207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GDF-8 upregulates MMP2 (but not MMP9) expression in human extravillous cytotrophoblast (HTR-8/SVneo) cells via the ALK5-SMAD2/3 signaling pathway; knockdown of MMP2 attenuates GDF-8-induced cell invasiveness, linking the ALK5-SMAD2/3-MMP2 axis to trophoblast invasion.\",\n      \"method\": \"siRNA knockdown of ALK5, SMAD2/3, MMP2; immunoblot; invasion assay\",\n      \"journal\": \"Reproduction\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA epistasis with functional invasiveness readout; single lab\",\n      \"pmids\": [\"34432647\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GDF-8 stimulates aromatase (CYP19A1) expression and estradiol production in human granulosa-lutein cells via ALK5-mediated SMAD2/3 signaling; pharmacological blockade of ALK5 with SB431542 alleviates ovarian hyperstimulation syndrome symptoms and aromatase upregulation in a rat OHSS model.\",\n      \"method\": \"In vitro granulosa cell treatment, siRNA knockdown of ALK5/SMAD2/3, rat OHSS model, SB431542 pharmacological inhibition, ELISA\",\n      \"journal\": \"International Journal of Biological Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanism confirmed in vivo with pharmacological inhibition; single lab\",\n      \"pmids\": [\"34239360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GDF8 activates p38 MAPK signaling in cumulus cells and oocytes during in vitro maturation of porcine oocytes, acting through ActRIIb and Alk4/5 receptors; p38 MAPK phosphorylation alters downstream gene expression (Nrf2, Bcl-2, Has2, Ptx3, TNFAIP6) and reduces intracellular ROS, improving oocyte quality and embryo developmental competence.\",\n      \"method\": \"Receptor gene transcription assay, phospho-p38 immunoblot, gene expression analysis, ROS measurement, IVF/PA developmental assay\",\n      \"journal\": \"Theriogenology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor induction and p38 phosphorylation linked to functional outcome; single lab\",\n      \"pmids\": [\"28708509\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"MSTN attenuates pathological cardiac hypertrophy and excessive autophagy by directly inactivating AMPK/mTOR signaling and activating PPARγ/NF-κB signaling; additionally, MSTN downregulates miR-128 expression (induced by pressure overload/Ang II), preventing miR-128-mediated suppression of its target PPARγ, thereby maintaining the PPARγ/NF-κB axis.\",\n      \"method\": \"Myostatin knockout (MSTN-/-) mice, abdominal aorta coarctation model, Ang II treatment in vitro and in vivo, AMPK/mTOR/PPARγ/NF-κB pathway immunoblots, miR-128 overexpression/inhibition\",\n      \"journal\": \"Molecular Therapy – Nucleic Acids\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — knockout + pathway immunoblots + miRNA manipulation in vitro and in vivo; single lab\",\n      \"pmids\": [\"31923740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Suppression of myostatin by an anti-MSTN polyclonal antibody in diet-induced obese rats reverses insulin resistance by enhancing PI3K activity, Akt phosphorylation, GLUT4 expression, and mTOR phosphorylation, while inhibiting FoxO1 phosphorylation, without affecting GSK-3β phosphorylation, defining MSTN/PI3K/Akt/mTOR and MSTN/PI3K/Akt/FoxO1 as relevant signaling axes.\",\n      \"method\": \"Anti-MSTN antibody treatment in obese rats, PI3K activity assay, phospho-protein immunoblots, GLUT4 protein expression\",\n      \"journal\": \"Biotechnology Letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological inhibition in vivo with multiple pathway readouts; single lab\",\n      \"pmids\": [\"25048241\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Dual blockade of GDF8 and activin A (the two major ActRIIA/B ligands mediating muscle minimization) prevents GLP-1 receptor agonist-induced muscle loss and increases muscle mass in obese mice and non-human primates; this muscle preservation additionally enhances fat loss, demonstrating that GDF8 and activin A together are the principal ligands through which the ActRII receptor pathway reduces muscle mass.\",\n      \"method\": \"Dual antibody blockade in obese mouse and NHP models, body composition analysis (muscle/fat mass), GLP-1 agonist co-treatment\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — dual blockade in two independent animal models identifies GDF8+activin A as non-redundant ActRII ligands for muscle mass regulation\",\n      \"pmids\": [\"40360507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Myostatin deficiency leads to increased osteogenic differentiation of bone marrow-derived mesenchymal stem cells (BMSCs) in vitro; BMSCs express the myostatin receptor AcvrIIB, and recombinant myostatin decreases expression of osteogenic factors BMP-2 and IGF-1 in mechanically loaded BMSCs. This osteogenic advantage is abolished by unloading, indicating myostatin suppresses mechanosensitivity-dependent osteogenic factor expression.\",\n      \"method\": \"BMSC isolation from myostatin-null mice, osteogenic differentiation assays, immunofluorescence for AcvrIIB, recombinant myostatin treatment, hindlimb unloading model\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — receptor expression confirmed in target cells, gain/loss of function in vitro and in vivo; single lab\",\n      \"pmids\": [\"17383950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Myostatin treatment of bone marrow stromal cells (BMSCs) and epiphyseal growth plate chondrocytes inhibits their proliferation; myostatin suppresses chondrogenic differentiation of BMSCs by reducing collagen type II synthesis and significantly downregulating Sox9 mRNA expression, establishing a direct inhibitory role for myostatin in chondrogenesis.\",\n      \"method\": \"Proliferation assays on myostatin-deficient mouse BMSCs and chondrocytes, recombinant myostatin treatment, collagen type II ELISA, real-time PCR for Sox9\",\n      \"journal\": \"Growth Factors\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct recombinant protein treatment with defined molecular readout; single lab\",\n      \"pmids\": [\"21756198\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A single amino acid deletion in the MSTN propeptide region (deletion of cysteine 42, caused by a 3-bp deletion in exon 1) is sufficient to produce muscle hyperplasia (increased fiber number) without hypertrophy, and reduces fat pad weight in homozygous quail, demonstrating that cysteine 42 in the propeptide is functionally important for MSTN activity in avian species.\",\n      \"method\": \"CRISPR/Cas9 adenoviral gene editing in quail, genotyping, histology, body composition analysis\",\n      \"journal\": \"International Journal of Molecular Sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined single-residue deletion with characterized phenotypic readout in vivo\",\n      \"pmids\": [\"32098368\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Myostatin (MSTN/GDF8) is synthesized as a precursor that is proteolytically processed into a propeptide–C-terminal dimer latent complex; tolloid metalloproteases cleave the prodomain at D99 (requiring Y94 and D92 for recognition) to activate the latent complex, and the active C-terminal dimer signals by binding ActRIIB (primarily) or ActRIIA, which recruits ALK4 or ALK5 as a type I receptor to phosphorylate Smad2/Smad3 and simultaneously suppresses Akt/mTOR/p70S6K, thereby inhibiting myoblast differentiation, reducing myotube size, blocking adipogenesis (via BMP7/ActRIIB competition), and suppressing osteogenic and chondrogenic differentiation; endogenous inhibition is achieved by noncovalent binding of the propeptide, FLRG, and GASP-1 in serum, and by follistatin/WFIKKN2 (which block type II receptor access), while NF-κB directly drives myostatin transcription under hyperammonemic conditions and SMAD2/3 represses the TET1 demethylase promoter to maintain hypermethylation of myogenic genes.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"Myostatin (MSTN/GDF8) is a TGF-β family ligand that functions as a systemic negative regulator of skeletal muscle mass, bone formation, and chondrogenesis, while also modulating reproductive cell function and cardiac autophagy. It is synthesized as a latent complex in which the prodomain noncovalently inhibits the mature C-terminal dimer; activation requires tolloid metalloprotease cleavage of the prodomain at D99, with residues Y94 and D92 critical for protease recognition [PMID:33876824]. The released mature ligand signals through type II receptors ActRIIA/B and type I receptors ALK4/5 to phosphorylate SMAD2/3, which suppresses muscle satellite cell proliferation and differentiation, inhibits osteoblast differentiation while promoting osteoclastogenesis, and transcriptionally regulates downstream targets including TET1, IGFBP-3, SERPINE1, MMP2, and FSTL3 [PMID:25368322, PMID:32210722, PMID:28074479, PMID:33195207]. Extracellular antagonists including its own propeptide, follistatin, FSTL3, and the WFIKKN2 follistatin domain block ligand–receptor interaction through structurally distinct binding modes, and loss-of-function mutations in cattle cause the double-muscling phenotype [PMID:9314496, PMID:11519824, PMID:30814254].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing myostatin as a negative regulator of muscle mass: independent loss-of-function alleles in two cattle breeds converged on the same double-muscling phenotype, proving that GDF8 restrains skeletal muscle growth in vivo.\",\n      \"evidence\": \"Sequence analysis of two independent natural mutations (11-bp deletion in Belgian Blue, C→Y missense in Piedmontese) in cattle\",\n      \"pmids\": [\"9314496\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of action on muscle cells unknown\", \"Receptor identity and downstream signaling uncharacterized\", \"Whether myostatin acts on tissues other than muscle not addressed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identifying the prodomain as an endogenous inhibitor resolved how myostatin circulates in a latent form: the propeptide forms a noncovalent complex that blocks receptor binding and suppresses signaling activity.\",\n      \"evidence\": \"Size exclusion chromatography, chemical crosslinking, competitive receptor-binding on L6 myoblasts, and CAGA12 reporter assay in A204 cells\",\n      \"pmids\": [\"11519824\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Protease responsible for activating the latent complex not identified\", \"Structural basis of prodomain–mature domain interaction unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Linking myostatin's anti-proliferative effect to IGFBP-3 induction provided the first downstream effector mechanism: GDF8 treatment upregulates IGFBP-3, and neutralizing IGFBP-3 partially reverses growth suppression.\",\n      \"evidence\": \"PEMC proliferation assays, RT-PCR/western blot for IGFBP-3, antibody neutralization\",\n      \"pmids\": [\"14502562\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Partial rescue suggests additional effector pathways\", \"SMAD dependence of IGFBP-3 induction not tested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Demonstrating ActRIIB expression on bone marrow mesenchymal stem cells and myostatin-dependent suppression of osteogenesis extended the ligand's role beyond skeletal muscle to bone biology.\",\n      \"evidence\": \"Immunofluorescence for AcvrIIB on BMSCs, osteogenic differentiation comparing Mstn-KO vs. WT, recombinant myostatin treatment\",\n      \"pmids\": [\"17383950\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct signaling pathway in osteoblast lineage not dissected\", \"In vivo bone phenotype not systematically characterized at this point\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Myostatin was shown to directly inhibit chondrogenesis by suppressing Sox9 and collagen II, broadening its skeletal role to cartilage development.\",\n      \"evidence\": \"In vitro chondrogenic differentiation with recombinant myostatin, RT-PCR for Sox9, western blot for collagen II, Mstn-KO chondrocyte proliferation assays\",\n      \"pmids\": [\"21756198\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor and SMAD dependence not tested in chondrocytes\", \"In vivo growth plate phenotype not characterized\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Structural and pharmacological dissection of signaling showed that GDF8 signals through ALK4/5 to phosphorylate SMAD2/3, and that small molecule type I receptor inhibitors can rescue myogenic differentiation.\",\n      \"evidence\": \"Crystal structure of ActRIIA:dorsomorphin complex, SMAD2/3 phosphorylation assays, myoblast differentiation and contractile myotube formation assays\",\n      \"pmids\": [\"25368322\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contributions of ALK4 vs. ALK5 in different tissues not resolved\", \"In vivo therapeutic efficacy of these inhibitors not demonstrated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Crystal structures of apo-GDF8 and apo-GDF11 revealed that differences in the type I receptor binding site explain GDF11's greater signaling potency, and that chimeric residue swaps enhance GDF8 activity, establishing the structural basis for ligand specificity within this subfamily.\",\n      \"evidence\": \"Crystal structures (apo-GDF8, apo-GDF11, GDF11:FS288), chimeric mutagenesis, SMAD2/3 reporter assays\",\n      \"pmids\": [\"28257634\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full ternary signaling complex structure not determined\", \"Whether potency differences translate to in vivo tissue-specific effects unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"GDF8 was shown to directly inhibit osteoblast differentiation and promote RANKL-induced osteoclastogenesis in vitro and in vivo, establishing it as a dual-acting bone catabolic factor.\",\n      \"evidence\": \"Osteoblast/osteoclast differentiation assays, in vivo recombinant GDF8 injection and neutralizing antibody treatment with histomorphometry\",\n      \"pmids\": [\"28074479\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling pathway mediating osteoclast promotion not identified\", \"Whether bone effects are direct or secondary to muscle changes in vivo not fully resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"High-resolution crystal structure of the WFIKKN2 follistatin domain revealed a structurally distinct mechanism for GDF8 antagonism compared to follistatin and FSTL3, expanding the repertoire of extracellular inhibitors with known binding modes.\",\n      \"evidence\": \"1.39 Å crystal structure, native gel shift, SPR, alanine-scanning mutagenesis, cell-based antagonism assays\",\n      \"pmids\": [\"30814254\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full-length WFIKKN2–GDF8 complex structure not solved\", \"Relative in vivo contributions of different extracellular antagonists not determined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Multiple downstream pathways were delineated in non-muscle tissues: GDF8 upregulates SERPINE1 via ALK5-SMAD2/3-SMAD4 (requiring TP53) in granulosa cells to impair glucose metabolism, and attenuates cardiac hypertrophy by inhibiting autophagy via AMPK/mTOR and activating PPARγ/NF-κB signaling.\",\n      \"evidence\": \"siRNA knockdowns of pathway components in granulosa cells, glucose metabolism assays; aortic coarctation and Ang II models in Mstn-KO mice, miR-128 manipulation in cardiomyocytes\",\n      \"pmids\": [\"33425488\", \"31923740\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"AMPK/mTOR regulation mechanism not biochemically defined\", \"Whether cardiac and reproductive signaling branches share downstream mediators not addressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"The epigenetic arm of MSTN signaling was established: SMAD2/3 directly binds the TET1 promoter to repress its expression, linking MSTN to DNA demethylation control during myogenic differentiation.\",\n      \"evidence\": \"ChIP-qPCR showing SMAD2/3 at TET1 promoter, bisulfite sequencing, TET1 overexpression/knockdown in satellite cells\",\n      \"pmids\": [\"32210722\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Genome-wide methylation targets of TET1 downstream of MSTN not mapped\", \"Whether TET1 regulation occurs in non-muscle tissues unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"GDF8 signaling through ALK5-SMAD2/3 was shown to promote trophoblast invasion via upregulation of FSTL3 and MMP2, extending its functional repertoire to placental biology.\",\n      \"evidence\": \"siRNA knockdowns in EVT and HTR-8/SVneo cells, Matrigel invasion assays, western blot/RT-PCR for FSTL3 and MMP2\",\n      \"pmids\": [\"33195207\", \"34432647\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance to placentation not tested\", \"Whether GDF8 is produced locally or acts systemically on trophoblast unclear\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Genetic epistasis between MSTN and GDF11 in bone was resolved: Mstn deletion upregulates Gdf11 which activates BMP signaling to enhance bone formation, while follistatin overexpression (blocking both) causes fractures, demonstrating non-redundant roles.\",\n      \"evidence\": \"Gdf11, Mstn, double-null, and follistatin-overexpressing mouse models; osteoblast/chondrocyte assays; BMP signaling analysis\",\n      \"pmids\": [\"32071240\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Mstn loss transcriptionally upregulates Gdf11 not determined\", \"Whether compensatory cross-regulation occurs in muscle not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"The activation mechanism was biochemically defined: tolloid metalloproteases cleave the prodomain at D99, with Y94 and D92 serving as critical recognition determinants; mutation of these residues creates dominant-negative latent complexes.\",\n      \"evidence\": \"Systematic alanine mutagenesis of GDF8 prodomain, in vitro tolloid (Tll1 astacin domain) cleavage assays, dominant-negative co-expression experiments\",\n      \"pmids\": [\"33876824\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which tolloid family member(s) are physiologically relevant in vivo not resolved\", \"Whether prodomain cleavage is tissue-specific not known\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"GDF8 and activin A were identified as the two principal ActRIIA/B ligands responsible for muscle minimization, and their dual blockade prevents GLP-1 agonist-induced muscle loss while enhancing fat loss.\",\n      \"evidence\": \"Dual antibody blockade in diet-induced obese mice and non-human primates on GLP-1 agonist treatment; body composition measurements\",\n      \"pmids\": [\"40360507\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of GDF8 vs. activin A to muscle loss not individually quantified in vivo\", \"Long-term safety and metabolic effects of dual blockade not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full ternary signaling complex structure, the tissue-specific hierarchy among tolloid family proteases for latent complex activation, and the relative in vivo contributions of the multiple extracellular antagonists (propeptide, follistatin, FSTL3, WFIKKN2) in different physiological contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No ternary type I/type II receptor–ligand complex structure available\", \"Tissue-specific tolloid protease identity for in vivo activation not defined\", \"Quantitative in vivo contributions of individual extracellular antagonists not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [1, 5, 6, 9]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 7, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 8, 16, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [5, 6, 9, 14]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 6, 9, 14]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 4, 7, 12]}\n    ],\n    \"complexes\": [\n      \"Latent GDF8 prodomain–mature dimer complex\"\n    ],\n    \"partners\": [\n      \"ACVR2A\",\n      \"ACVR2B\",\n      \"ALK5\",\n      \"SMAD2\",\n      \"SMAD3\",\n      \"WFIKKN2\",\n      \"FST\",\n      \"FSTL3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"Myostatin (MSTN/GDF8) is a secreted TGF-β superfamily member that functions as a master negative regulator of skeletal muscle mass and additionally suppresses osteogenic, chondrogenic, and adipogenic differentiation. It is synthesized as a precursor that is proteolytically processed into a latent complex of a disulfide-linked C-terminal dimer held noncovalently by the propeptide; activation requires tolloid metalloprotease cleavage of the prodomain at D99, with recognition dependent on Y94 and D92 [PMID:33876824]. The active dimer signals primarily through ActRIIB (and ActRIIA), recruiting ALK4 or ALK5 as type I receptors to phosphorylate Smad2/Smad3, which inhibits myoblast differentiation, suppresses the Akt/mTOR/p70S6K protein synthesis axis, and epigenetically maintains hypermethylation of myogenic gene promoters by repressing TET1 transcription [PMID:19357233, PMID:32210722, PMID:14517293]. Loss-of-function mutations in MSTN cause dramatic skeletal muscle hypertrophy and hyperplasia in mice, cattle, and humans [PMID:9139826, PMID:9314496, PMID:15215484].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Establishing myostatin as a negative regulator of muscle growth: targeted disruption in mice and natural loss-of-function mutations in cattle independently demonstrated that MSTN loss causes 2–3× increases in skeletal muscle mass through both hyperplasia and hypertrophy, defining the gene's core biological function.\",\n      \"evidence\": \"Knockout mouse phenotyping (Nature) and cattle breed mutation identification (Genome Research, PNAS)\",\n      \"pmids\": [\"9139826\", \"9314496\", \"9356471\", \"9288100\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of action and receptor identity unknown\", \"Relative contribution of hyperplasia vs. hypertrophy unresolved\", \"No human validation yet\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defining the latent complex and receptor system: biochemical studies showed that mature myostatin is a disulfide-linked C-terminal dimer held in an inactive complex by its propeptide, which directly blocks receptor binding; the dimer binds ActRIIB with high affinity and ActRIIA with lower affinity, and transgenic overexpression of the propeptide, follistatin, or dominant-negative ActRIIB phenocopied myostatin knockouts.\",\n      \"evidence\": \"Protein purification, receptor binding assays, size exclusion chromatography, chemical crosslinking, and transgenic mouse muscle phenotyping\",\n      \"pmids\": [\"11459935\", \"11519824\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Type I receptor partners not yet identified\", \"Mechanism of latent complex activation unknown\", \"Intracellular signaling cascade uncharacterized\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mapping the intracellular signaling pathway and identifying endogenous serum inhibitors: myostatin was shown to signal through ALK4/ALK5 to phosphorylate Smad2/3, and two additional endogenous inhibitory proteins—FLRG and GASP-1—were identified in serum complexes with myostatin alongside the propeptide, establishing a multi-layered extracellular regulation system.\",\n      \"evidence\": \"Receptor co-IP, siRNA knockdown, reporter assays, affinity purification/MS from serum, recombinant protein binding\",\n      \"pmids\": [\"14517293\", \"12194980\", \"12595574\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative stoichiometric contributions of propeptide, FLRG, GASP-1, and follistatin in vivo unclear\", \"Cross-talk with non-Smad pathways not defined\", \"Mechanism of latent complex activation still unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Human genetic validation: identification of a loss-of-function MSTN mutation in a child with exceptional muscle hypertrophy confirmed that myostatin's role as a muscle growth inhibitor is conserved in humans.\",\n      \"evidence\": \"Clinical genetics and MSTN gene sequencing in a hyper-muscular child\",\n      \"pmids\": [\"15215484\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Only a single human case reported\", \"Dose-response and heterozygous phenotype in humans poorly defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Dissecting Akt/mTOR suppression as a parallel mechanism: myostatin was shown to inhibit the Akt/mTOR/p70S6K protein synthesis pathway in a Smad2/3-dependent manner, with reciprocal cross-talk whereby TORC1 blockade amplifies Smad2 phosphorylation, explaining myostatin's ability to reduce myotube size independently of atrophy E3 ligases.\",\n      \"evidence\": \"siRNA knockdown of RAPTOR/RICTOR, phospho-protein immunoblots, myotube diameter measurements\",\n      \"pmids\": [\"19357233\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking Smad2/3 to Akt suppression not fully resolved\", \"In vivo validation of cross-talk incomplete\", \"Atrophy-independent fiber size reduction mechanism unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identifying transcriptional regulation of MSTN itself: NF-κB p65 was shown to bind directly to the myostatin promoter under hyperammonemic conditions, driving transcriptional upregulation—a mechanism linking liver disease–associated sarcopenia to myostatin.\",\n      \"evidence\": \"ChIP on myostatin promoter, NF-κB siRNA and IKK inhibitor in C2C12 myotubes and mouse hyperammonemia model\",\n      \"pmids\": [\"24145431\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Other transcriptional regulators of MSTN promoter not systematically identified\", \"Whether NF-κB drives MSTN in non-hepatic wasting conditions unknown\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Structural basis for signaling specificity: crystal structures of apo-GDF8 and apo-GDF11 revealed that despite 90% sequence identity, unique features in the type I receptor binding site explain GDF11's higher SMAD2/3 signaling potency, and chimeric mutagenesis confirmed these residues as determinants of signaling output.\",\n      \"evidence\": \"X-ray crystallography, chimeric mutagenesis, SMAD2/3 phosphorylation assays\",\n      \"pmids\": [\"28257634\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full ternary complex structure (ligand–type I–type II) not solved\", \"Structural basis for differential receptor recruitment in cells unknown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Structural mechanism of WFIKKN2 inhibition: crystallography and mutagenesis demonstrated that the WFIKKN2 follistatin domain blocks GDF8 access to ActRIIB through binding contacts distinct from those used by follistatin or FSTL3, revealing non-redundant modes of extracellular antagonism.\",\n      \"evidence\": \"1.39 Å crystal structure of WFIKKN2 FSD, SPR, native gel shift, alanine-scanning mutagenesis\",\n      \"pmids\": [\"30814254\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full WFIKKN2–GDF8 co-crystal structure not available\", \"In vivo contribution of WFIKKN2 vs. other antagonists not quantified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Epigenetic mechanism downstream of Smad signaling: SMAD2/3 occupancy at the TET1 promoter was shown to repress TET1 demethylase transcription, maintaining DNA methylation at myogenic gene promoters (PAX3, PAX7, MyoD, MyoG); MSTN loss derepresses TET1, reducing methylation and promoting differentiation.\",\n      \"evidence\": \"ChIP-qPCR for SMAD2/3 at TET1 promoter, bisulfite sequencing, TET1 knockdown/overexpression in MSTN+/- satellite cells\",\n      \"pmids\": [\"32210722\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab finding awaiting independent replication\", \"Whether TET1 regulation is muscle-specific or systemic unknown\", \"Contribution relative to direct transcriptional Smad targets not quantified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defining prodomain activation mechanism: tolloid metalloproteases were shown to cleave the GDF8 prodomain at D99, with Y94 and D92 identified as critical recognition residues; tolloid-resistant prodomain mutants act as dominant-negative inhibitors.\",\n      \"evidence\": \"In vitro cleavage assay with Tll1 astacin domain, alanine-scanning mutagenesis, reporter assays\",\n      \"pmids\": [\"33876824\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo validation of tolloid-dependent activation kinetics missing\", \"Structural basis of tolloid–prodomain recognition not solved\", \"Alternative activation pathways (e.g., acid pH) not fully characterized\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Demonstrating non-redundancy of GDF8 and activin A: dual antibody blockade of both ligands—but not either alone—fully prevented GLP-1 agonist–induced muscle loss and enhanced fat loss in obese mice and NHPs, establishing GDF8 and activin A as the two principal ActRII ligands limiting muscle mass.\",\n      \"evidence\": \"Dual antibody blockade in obese mouse and non-human primate models with body composition analysis\",\n      \"pmids\": [\"40360507\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of each ligand to muscle vs. fat regulation not individually quantified\", \"Long-term safety of dual blockade unknown\", \"Whether other ActRII ligands contribute in specific disease contexts untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full ternary structure of the GDF8–type I–type II receptor signaling complex, the quantitative in vivo contributions of each extracellular antagonist (propeptide, FLRG, GASP-1, follistatin, WFIKKN2), the complete set of transcriptional regulators of the MSTN promoter beyond NF-κB, and the mechanistic basis for myostatin's non-muscle roles in cardiac, bone, and reproductive tissues.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ternary receptor complex structure unsolved\", \"Systematic in vivo dissection of antagonist hierarchy lacking\", \"Non-muscle signaling mechanisms poorly defined at molecular level\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 2, 8, 25]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [5, 9, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [2, 3, 4, 6, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 9, 17]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [0, 1, 8, 26, 27]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [24]},\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [2, 3, 15]}\n    ],\n    \"complexes\": [\n      \"Latent myostatin complex (propeptide–mature GDF8 dimer)\"\n    ],\n    \"partners\": [\n      \"ACVR2B\",\n      \"ACVR2A\",\n      \"ACVR1B\",\n      \"TGFBR1\",\n      \"FSTL3\",\n      \"WFIKKN2\",\n      \"FLRG\",\n      \"FSTL1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}